PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 1A PHASE 1, OPEN -LABEL, 3-TREATMENT, 6-SEQUENCE, 3- PERIOD 
CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF -07321332/RITONAVIR
AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN 
HEALTHY PARTICIPANTS
Study Intervention Number: PF-07321332
Study Intervention Name: N/A
US IND Number: 153517
EudraCT Number: 2021- 003590- 62
ClinicalTrials.gov ID: N/A
Protocol Number: C4671012
Phase: 1
Brief Title: A Phase 1 Study  to Estimate the Effect of PF-07321332/Ritonavir and 
Ritonavir on the PK of Dabigatran in Healthy  Participants
This document and accompanying materials contain confidential information belonging to Pfizer. Except as 
otherwise agreed to in writing, by accepting or 
reviewing these documents, you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by applicable law ) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligati on, Pfizer 
must be promptly notified.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date
Original protocol 03August 2021

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES................................................................................................................. ....8
1. PROTOCOL  SUMMARY.....................................................................................................9
1.1. Synopsis .................................................................................................................. ..9
1.2. Schema .................................................................................................................... 15
1.3. Schedule of Activities .............................................................................................16
2. INTRODUCTION ...............................................................................................................2 5
2.1. Study R ationale .......................................................................................................25
2.2. Background .............................................................................................................26
2.2.1. Nonclinical Pharmacology..........................................................................262.2.2. Nonclinical Pharmacokinetics and Metabolism .........................................262.2.3. Nonclinical Safety ......................................................................................272.2.4. Clinical Overview.......................................................................................27
2.2.4.1. Safety Overview........................................................................28
2.2.4.2. Summary of PF-07321332 Pharmacokinetics in Human..........28
2.3. Benefit/Risk Assessment.........................................................................................29
2.3.1. Risk Assessment .........................................................................................302.3.2. Benefit Assessment.....................................................................................332.3.3. Overall Benefit/Risk Conclusion................................................................33
3. OBJECTIVES AND ENDPOINTS .....................................................................................334. STUDY DESIGN................................................................................................................ .33
4.1. Overall Design.........................................................................................................334.2. Scientific Rationale for Study Design.....................................................................35
4.2.1. Choice of Contraception/Barrier Requirements .........................................37
4.3. Justification for Dose ..............................................................................................37
4.4. End of Study Definition ..........................................................................................37
5. STUDY POPULATION ......................................................................................................37
5.1. Inclusion Criteria.....................................................................................................38
5.2. Exclusion Criteria....................................................................................................385.3. Lifestyle Cons iderations..........................................................................................42
CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 45.3.1. Vaccine and Exposure to Infections Guidelines ................................ ......... 42
5.3.2. Meals and Dietary  Restrictions ...................................................................42
5.3.3. Caffeine, Alcohol, and Tobacco .................................................................43
5.3.4. Activity .......................................................................................................43
5.3.5. Contracepti on
..............................................................................................43
5.4. Screen Failures ........................................................................................................44
6. STUDY INTERVENTIO N(S) AND CONCOMITANT THERAPY .................................44
6.1. Study  Intervention(s) Administered ........................................................................44
6.1.1. Administration ............................................................................................44
6.2.Preparation, Handling, Storage, and Accountability ...............................................45
6.2.1. Preparation and Dispensing ........................................................................46
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................46
6.3.1. Allocation to Study Intervention ................................................................46
6.4. Study  Intervention Compliance ...............................................................................46
6.5. Dose Modification ...................................................................................................47
6.6. Continued Access to Study  Intervention After the End of the Study ...................... 47
6.7. Treatment of Overdose............................................................................................47
6.8. Concomitant Therapy ..............................................................................................47
6.8.1. Rescue 
Medicine .........................................................................................48
7. DI SCONTINUATION O F STUDY INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................48
7.1. Discontinuation of Study  Intervention ....................................................................48
7.1.1. ECG Changes ..............................................................................................49
7.1.2. Potential Cases of Acute Kidney  Injury ................................ ..................... 49
7.1.3. L iver Injury .................................................................................................50
7.2. Participant Discontinuation/Withdrawal From the Study .......................................50
7.2.1. Withdrawal of Consent ................................ ................................ ............... 50
7.3. L ost to Follow -Up...................................................................................................51
8. STUDY ASSESSMENTS AND PROCEDURES ...............................................................51
8.1. Efficacy  Assessments ..............................................................................................52
8.2. Saf ety Assessments .................................................................................................52
8.2.1. Phy sical Examinations ................................................................................53

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 58.2.2. Vital Signs ..................................................................................................53
8.2.2.1. Respiratory Rate........................................................................538.2.2.2. Temperature ..............................................................................54
8.2.3. Electrocardiograms.....................................................................................548.2.4. Clinical Safety La boratory Asse ssments ....................................................55
8.2.5. COVID-19 Specific Assessments...............................................................558.2.6. Pregnancy Testing ......................................................................................55
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting .................56
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......56
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................578.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................57
8.3.2. Method of Detecting AEs and SAEs ..........................................................578.3.3. Follow-up of AEs and SAEs.......................................................................588.3.4. Regulatory Reporting Requirements for SAEs...........................................588.3.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure .....................................................58
8.3.5.1. Exposure During Pregnancy......................................................598.3.5.2. Exposure During Breastfeeding ................................................608.3.5.3. Occupational Exposure .............................................................61
8.3.6. Cardiovascular and Death Events...............................................................618.3.7. Disease Related-Events and/or Disease Related- Outcomes Not 
Qualifying as AEs or SAEs..............................................................................61
8.3.8. Adverse Events of Special Interest.............................................................61
8.3.8.1. Lack of Efficacy........................................................................61
8.3.9. Medical Device Deficiencies......................................................................618.3.10. Medication Errors .....................................................................................61
8.4. Pharmacokinetics ....................................................................................................62
8.4.1. Plasma for Analysis of PF-07321332, Ritonavir, and Dabigatran .............62
CCI
PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 68.7. Immunogenicity Assessments .................................................................................64
8.8. Health Economics ...................................................................................................64
9. STATISTICAL C ONSIDERATIONS ................................................................................64
9.1. Statistical Hypotheses .............................................................................................649.2. Analysis Sets ...........................................................................................................649.3. Statistical Analyses .................................................................................................65
9.3.1. Pharmacokinetic Analyses..........................................................................65
9.3.1.1. Derivation of Pharmacokinetic Parameters Prior to 
Analysis .............................................................................................65
9.3.2. Statistical Methods for PK Data .................................................................669.3.3. Other Safety Analyses ................................................................................67
9.4. Interim Analyses .....................................................................................................67
9.5. Sample Size Determination.....................................................................................67
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS ..........................................................................................................69
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ...............69
10.1.1. Regulatory and Ethical Considerations ....................................................69
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP.........................................................................69
10.1.2. Informed Consent Process ........................................................................7010.1.3. Data Protection .........................................................................................7110.1.4. Committees Structure ...............................................................................71
10.1.4.1. Data Monitoring Committee ...................................................71
10.1.5. Dissemination of Clinical Study Data ......................................................7110.1.6. Data Qualit y Assurance ............................................................................72
10.1.7. Source Documents....................................................................................7410.1.8. Study and Site Start and Closure ..............................................................74
10.1.9. Publication Policy.....................................................................................75CCI
CCI
PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 710.1.10. Sponsor’s Qualified Medical Personnel .................................................76
10.2. Appendix 2: Clinical Laboratory Tests .................................................................7710.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ......................................................................78
10.3.1. Definition of AE .......................................................................................7810.3.2. Definition of an SAE ................................................................................7910.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs During 
the Active Collection Period............................................................................80
10.3.4. Reporting of SAEs....................................................................................84
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................................85
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................8510.4.2. Female Participant Reproductive Inclusion Criteria.................................8510.4.3. Woman of Childbearing Potential ............................................................8610.4.4. Contraception Methods.............................................................................87
10.6. Appendix 6: Liver Safety: Suggested Actions and Follow-Up Assessments .......90
10.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................9210.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That 
May Result in DDI ....................................................................................................94
10.9. Appendix 9: Abbreviations ...................................................................................97
11. REFERENCES ................................................................................................................1 01
CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 8LIST OF TABLES
Table 1. Plasma PK Parameters ................................ ................................ .............. 65
Table 2. Protocol -Required Safet y Laboratory  Assessments .................................77

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title: A Phase 1 Study  toEstimate the Effect of PF-07321332/Ritonavir and 
Ritonavir on the PK of Dabigatran in Healthy  Participants
Rationale
PF-07321332 is a potent and selective inhibitor of the SARS -CoV -2 3CL  proteas e that is 
currentl y being developed as an oral treatment of COVID -19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipated to be efficacious. 
In vitro and in vivo metabolite profiling suggests that the primary  clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. I n a reaction phenot yping study using human 
liver microsomes in the presence of selective CYP inhibitors, CY P3A4 was predicted to be 
the major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF- 07321332. As 
such, in the FIH stud y, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF- 07321332 in order to achieve plasma l evels that are anticipated to be 
efficacious. Preliminary  PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/100 mg q12h suggest 
that the renal pathway  may  also play  a significant role in PF -07321332 excretion when 
co-administered with ritonavir, with approximately  32.5% (PF ‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at stead y-state, and renal clearance ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively  metabolized, primarily  by CYP3A4.1
The DDI potential of PF- 07321332 was further evaluated using a static mechanistic model
using the projected C max for reversible inhibition or C av time-dependent inhibition in plasma,
intestinal lumen, enterocy tes, liver, and portal inlet (incorporating k p,uu and k a). Based on this
model, PF -07321332 has minimal risk to inhibit CYPs other than 3A4, UGTs and transport 
proteins; however, the potential remains to reversibly  and time -dependentl y inhibit CYP3A4 
and inhibit P -gp in humans at the proposed therapeutic dose. 
Dabigatran etexilate (herein referred to as dabigatran) is a sensitive probe substrate of the 
efflux transporter P -gp that experiences a ≥2fold increase in exposure upon coadministration 
with P -gp inhibitors verapamil or quinidine.2Additionally , dabigatran is primarily  renall y 
eliminated by  glomerular filtration ( approximately 80%).2
Ritonavir is classified as a P -gp inhibitor. Although limited clinical data exist on drug- drug 
interactions with ritonavir and P- gp probe substrates like dabigatran, results from astudy  
assessing the concomitant administration of dabigatran etexilate and ritonavir did not result 
in statistically  significant changes in an y of the PK parameters of dabigatran or changes in 
thrombin time measures as compared to dabigatran administered alone. However, there was 
statist ically  significant and similar decreases in the dabigatran AUC and C maxwhen 
dabigatran and ritonavir were administered separately  by 2 hours compared to values 

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 10obtained when dabigatran was administered alone, suggesting there may be the potential of 
ritonavir to induce P-gp. Even though dabigatran is primarily renally eliminated, resultssuggested that whether dabigatran and ritonavir were administered simultaneously or separated by 2 hours, there was no change in dabigatran t
½or K elcompared to dabigatran 
administered alone.2
Based on available data to date, it is possible that administration of a P-gp substrate, dabigatran with PF ‑07321332/ritonavir may lead to changes in exposures of dabigatran.
3
Therefore, results of this study will provide guidance for dosing with substrates of P-gp.
The purpose of this study is to estimate the effect of PF-07321332/ritonavir and ritonavir on 
the PK of dabigatran in healthy participants.
Objectives and Endpoints
Objectives Endpoints
Primary: Primary:
•To estimate the effect of the multiple doses of 
PF-07321332/ritonavir co-administered with dabigatran orally (test) compared to dabigatran administered orally as a single dose (reference).•Plasma dabigatran (total) PK parameters: C
max,
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated).
Secondary: Secondary: 
•To estimate the effect of the multiple doses of 
ritonavir co-administered with dabigatran orally 
(test) compared to dabigatran administered orally as a single dose (reference).
•To evaluate the safety and tolerability of 
dabigatran alone and following
co-administration with multiple dosing of PF-07321332/ritonavi r or ritonavir
•To characterize the PK of dabigatran and 
PF-07321332 in study treatments.•Plasma dabigatran (total) PK parameters: C
max,
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated).
•Safety: TEAEs, clinical laboratory tests, vital 
signs, PE, and ECGs.
•Dabigatran (total): T max, t½, as data permit
•PF-07321332: C max, AUC tau, Tmax, t½, CL/F, 
Vz/F.
 
 
Overall Design
Brief SummaryThis is a Phase 1, open-label, randomized, 3-treatment, 6-sequence, 3-way crossover design 
to estimate the effect of PF-07321332/ritonavir and ritonavir on the PK of dabigatran in healthy participants. A total of approximately 24 healthy male and/or female participants will CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 11be enrolled into the stud y. The purpose of this study  is to estimate the effect of 
PF-07321332/ritonavir and ritonavir on the PK of dabigatran in healthy  participants. Safety  
and tolerability  will also be assessed throughout the duration of the study . This study  will 
consist of 3 treatments. Treatment 1 (T1) will include administration of dabigatran 
administered as a 75 mg single oral dose on Day 1 followed by  a 3-day washout. Treatment 2 
(T2) will include multiple dose administration of PF -07321332/ritonavir 300 mg/100 mg 
q12h for 2 days (Day s1 and 2). On the second day  of T2 (Day  2) in the morning, a single 
oral dose of dabigatran 75 mg will be administered, followed b y a 3 -day washout. 
Treatment 3 (T3) will include multiple dose administration of ritonavir 100 mg q12h for 2 
days (Day s 1 and 2). On the second day  (Day 2)in the morning , dabigatran will be 
administered as a single oral 75 mg dose. PK sampling over 48 hours will be included in all 
3treatments to determine PK parameters. Each washout period will begin after the first dose 
of study  treatment in that treatment period .
Each pa rticipant will be screened to determine eligibility  within 28 days prior to study  
treatment. Eligible participants will report to the CRU at least 12 hours prior to Day 1 dosing 
in Period 1 and will be required to stay  in the CRU for 13 day s and 12 nights.
The following describes the study
 design as an example for Sequence 1 (T1-T2-T3):
Participants in T1 (Day  1) will receive dabigatran orally  administered as a 75 mg dose 
followed b y a 3 -day washout. Serial PK samples will be collected up to 48 hours after single 
dose administration to determine PK parameters. 
T2 will begin on Study  Day  5 (referred to as T2 Day 1). Participants in T2 (Day  1) will 
receive multiple doses of PF -07321332/ritonavir 300 mg/100 mg q12h on Day s1 and 2 
followed b y a single dose of 75 mg dabigatran administered orally  on Day  2, followed by  a 
3-day washout. Serial PK samples will be collected up to 48 hours following the 
administration of PF -07321332/ritonavir co
-administered with a single oral dose of 75 mg 
dabigatran. 
T3 will begi n on Study  Day  10 (referred to as T3 Day  1). Participants in T3 (Day  1) will 
receive multiple dose administration of ritonavir 100 mg q12h on Day s 1 and 2. On Day  2, 
participants will be administered a single oral 75 mg dose of dabigatran. Serial PK sample s 
will be collected up to 48 hours following the administration of ritonavir 100 mg q12h 
co-administered with a single oral dose of 75 mg dabigatran. 
Eligible participants will be admitted to the CRU on Day  -1 (at least 12 hours prior to Day 1 
dosing of d abigatran dosing on Day 1) and will be confined in the CRU for 13 days and 
12nights. On the morning of Day 1 (T1), the participants will receive a single oral dose of 
75mg of dabigatran administered orall y, followed by a 3 -day washout. Serial blood sampl es 
at specified intervals will be collected up to 48 hours post
-dose for PK assessments . On the 
morning of Day 1 and Day  2 in T2, PF -
07321332/ritonavir 300 mg/100 mg will be 
administered as multiple doses q12h. Dabigatran 75 mg will be administered orally ,as a 
single dose on Day 2. On the morning of Day  1 and Day  2 in T3 participants will receive 
multiple dosing of ritonavir 100 mg q12h .On Day  2 of T3, participants will receive 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 12administration of a single oral dose of 75 mg dabigatran .Serial blood samples at specified 
intervals will be collected up to 48 hours post -dose for PK assessments of both ritonavir and 
dabigatran. Each washout period will begin after the first dose of study  treatmen t in tha t
treatment period .
All study  treatments, regardless of dosing regimen should be administered in the fasting 
condition. Specifically , morning doses should be followed by  an overnight fast of 
approximately  8-10 hours . When PK is performed after the morning dose, a 4- hour fast 
should occur. Evening dose will be admi nistered 1 hour before or 2 hours after a meal.   
Safety  assessments will be performed during Screening, on Day  -1 prior to dosing, and at 
specified time points. PE s, vital sign measurements, and clinical laboratory  tests will be 
conducted, and AEs will be monitored to assess safety . The total participation time (eg, CRU 
confinement time for study  procedures) for each participant in this study  is approximately  
13days/12 nights (excluding screening and follow -up contact). 
A safet y follow- up call will be ma de to participants 28 to 35 day s from administration of the 
final dose of stud y intervention.
Number of Participants
Approximately  24participants may  be enrolled to study  intervention. 
Note: 
“Enrolled ”means a participant, or his or her legally  authorized representative’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening. A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activity  after screening. Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified by  the 
protocol.
Intervention Groups and Duration
Each participant will be screened to determine eligibility  within 28 day s prior to study  
treatment. Eligible participants will report to the CRU at least 12 hours prior to Day  -1 and 
will be requi red to stay  in the CRU for 13 days and 12 nights. A safet y follow
-up call will be 
made to participants approximately  28 to 35 day s from administration of the final dose of 
study  intervention. 
Each enrolled participant will participate in 3 treatments and each washout period will begin 
after the first dose of study  treatment:
Treatment 1: In Treatment 1, dabigatran will be administered orally  as a 75 mg single 
dose in the morning followed by  a 3-day washout.  

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 13Treatment 2: In Treatment 2, PF -07321332/ritona vir 300 mg/100 mg q12h will be 
administered as multiple dose sover a period of 2 day s.Morning and evening doses 
will be administer edon Day  1, but only  the morning dose will be administered on 
Day 2.In the morning on Day  2, 75 mg of dabigatran will be ad ministered orally  as a 
single dose. Treatment 2 will be followed by  a 3-day washout.
Treatment 3: In Treatment 3, ritonavir 100 mg q12h will be administered as multiple 
dosesover a period of 2 day s.Morning and evening doses will be administered on 
Day 1,but only  the morning dose will be administered on Day  2. In the morning on 
Day 2, 75 mg of dabigatran will be administered orally  as a single dose.
Participants will randomly be assigned to 1 of 6 sequences as follows: 
Period 1 Period 2 Period 3
Sequence 1 Treatment 1 Treatment 2 Treatment 3
Sequence 2 Treatment 3 Treatment 1 Treatment 2
Sequence 3 Treatment 2 Treatment 3 Treatment 1
Sequence 4 Treatment 3 Treatment 2 Treatment 1
Sequence 5 Treatment 2 Treatment 1 Treatment 3
Sequence 6 Treatment 1 Treatment 3 Treatment 2
Participants will be discharged in T3, Study  Day 13 following completion of all assessments. 
The total planned duration of participation, from the Screening visit to the last Follow -up 
phone call, is approximately  11 weeks.
Data Monitoring Committee or Other Independent Oversight Committee: No
Statistical Methods
A sample size of approximately  24participants will provide adequate precision to estimate 
the effects of 
multiple dose PF-07321332 /ritonavir on the PK of single dose dabigatran .The 
expected widths of the 90% CIs with 80% coverage probability  are shown in the following 
table for a range of possible effects. 
Parameter Estimated Effect 
(100*Test/Reference)90% CI CI Width
AUC inf 80%
100%
120%
140%63.09%, 101.45%
78.86%, 126.81%
94.63%, 152.17%
110.40%, 177.53%38.36%
47.95%
57.54 %
67.13 %

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 14Parameter Estimated Effect 
(100*Test/Reference)90% CI CI Width
160%
180%126.17%, 202.89%
141.95%, 228.26%76.72 %
86.31%
Cmax 80%
100%
120%
140%
160%
180%60.49%, 105.80%
75.61%, 132.25%
90.74%, 158.70%
105.86%, 185.15%
120.98%, 211.60%
136.10%, 238.06%45.31%
56.64 %
67.97 %
79.30 %
90.62 %
101.95%
These estimates are based on the assumption that within -participant standard deviations are 
0.452 and 0. 532for lnAUC infand lnC max, respectively , as obtained from the mean of 
2 clinical stud ies(B1871043 and B7451026) and literature4in healthy  participants.
Participants who withdraw from the stud y ma y be replaced at the discretion of the 
investigator upon consultation with the sponsor.
Pharmacokinetics Analysis
The PK concentration population is defined as all participants assigned to investigational 
product and treated who have at least 1 concentration measured.
The PK parameter anal ysis population is defined as all participants assigned to 
investigational product and treated who have at least 1 of the PK parameters of primary  
interest measured.
Pharmacokinetic parameters for PF -07321332, ritonavir and dabigatran (total) will be 
analyzed by standard noncompartmental method of anal ysis. Actual PK sampling times will 
be used in the derivation of PF- 07321332, ritonavir and dabigatran PK parameters. The PF -
07321332, ritonavir and dabigatran plasma PK parameters will be summari zed descriptively  
by treatment. Plasma concentrations will be listed and summarized descriptively  by treatment 
and nominal PK sampling time. Individual participant and summary  profiles (mean and 
median plots) of the plasma concentration time data will be p lotted using actual and nominal 
times, respectivel y. Box and whisker plots of AUC inf, AUC tauand C maxwillbe plotted by  
treatment. 
Drug -Drug Interaction
Natural log transformed parameters ( AUC inf[ifdata permit ], AUC lastand C max)of dabigatran 
will be anal yzed using a mixed effect model with treatment, period and sequence as fixed 
effects and participant within sequence as a random effect. Estimates of the adjusted mean 
differences (Test -Reference) and corresponding 90% CIs will be obtained from the model. 
The adjusted mean differences and 90% CIs for the differences will be exponentiated to 
provide estimates of the ratio of adjusted geometric means (Test/Reference) and 90% CI for 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 15the ratios. Dabigatran administered alone will be th e reference treatment and 
PF-07321332/ritonavir co- administered with dabigatran and ritonavir co -administered with 
dabigatran will be the test treatments. 
Safety Analysis 
AEs, ECGs, vital signs ( BP, pulse rate, RR andtemperature )and safet y laboratory data will 
be reviewed and summarized on an ongoing basis during the stud y to evaluate the safet y of 
participants. An y clinical laboratory, ECG, BP, and pulse rate abnormalities of potential 
clinical concern will be described. Safet y data will be presented i n tabular and/or graphical 
format and summarized descriptivel y, where appropriate.
1.2.Schema
The following schematic represents the study  design as an example for Sequence 1.
Sequence 1 Period 1 Period 2 Period 3
Screening
Days -28 to -2Treatm ent 1
(Days 1 and 2)3-Day 
washoutaTreatm ent 
2
(Days 1 
and 2)3-Day 
washoutaTreatm ent 
3
(Days 1
and 2)Follow -
up
Days 
28-35
(Reference)
75 mg single o ral 
dose of dabigatran(Test)
PF-
07321332 
/ritonavir 
300/100 mg 
q12h 
multiple 
doses on 
Days 1 and 
2.bOn Day 
2, a single 
oral 75 mg 
dose of 
dabigatran  (Test)
Ritonavir 
100 mg 
q12h on 
Days 1 and 
2.bOn Day 
2, a single 
oral dose 
of 75 mg 
dose of 
dabigatran
a.The 3 -day washout will begin after the first dose of study medication.
b.Morning and evening doses will be administered on Day 1, but only the morning dose will be 
administered on Day 2. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 161.3.Schedule of Activities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well -being of the participant.
All SoA/PK sampling schedules below do not include day s of washout.
Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9 .ScreeningaTreatm ent (See Detailed SoA s Below for Each Treatm ent) Follow -Up Early 
Termination/
Discontinuation
Days Relative to Day 1 of 
Period 1Day -28 to 
Day -2Day -1 Day 13 28-35 Daysb
Hours After Dose
Informed consent X
CRU confinementcX        X
Inclusion/exclusion criteria X X
Medical/medication history 
(update)dX X
Physical examinationeX X X
Safety laboratoryfX X X
TSH & Free T4 X X
Dem ographygX
Pregnancy test (WOCBP only) X X X X
Contraception checkhX X X X X
FSHiX
Urine drug testingjX X
12-Lead ECGkX X X
Vital signs 
(BP/PR/RR /temperature )lX X X
HIV, HBsAg, HBsAb, HBcAb, 
HCVAb X

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 17Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9 .ScreeningaTreatment (See Detailed SoAs Below for Each Treatment) Follow-Up Early 
Termination/
Discontinuation
Days Relative to Day 1 of 
Period 1Day -28 to 
Day -2Day -1 Day 13 28-35 Daysb
Hours After Dose
COVID-19 questionnairemXX
COVID-19 testingnXX
COVID-19 check temperatureoXX X X X
Study intervention 
administrationp
PK blood samplingqX
Blood/Plasma ratio sam pler
 
CRU discharge X
Serious and nonserious AE 
monitoringX →→ → → → → → → → → →
a. Screening will be performed within 28 days prior to the first dose of study intervention. 
b. Contact may occur via telephone contact and must occur 28 to 35 days from administration of the final dose of study intervent ion.
c. Participants will be admitted to the CRU on Day -1. Participants will be discharged on Day 13 following the final assessments.  
d. Medical history will include a history of prior illegal drug, alcohol, and tobacco use, as well as blood donation within prio r 60 days. Medical history will be 
recorded at Screening and updated on Day -1 of Period 1. 
e. A PE will be performed by trained medical personnel at the investigator site at Screening and Day -1 of Period 1 only (height  and weight must be obtained 
at Screening to obtain BMI for eligibility criteria) and at Early Termination/Discontinuation. A brief PE may be performed at o ther designated time points 
at the discretion of the investigator. 
f. Safety laboratory assessments including urinalysis, hematology, chemistry and coagulation will be performed at the indicated time points. All the safety 
laboratory samples must be collected following at least a 4-hour fast. Additional safety laboratory assessments may be performe d at any time at the 
discretion of the investigator. 
g. Demographics will include participant race, ethnicity, age, and gender during the Screening visit. h. The investigator or his/her designee will discuss with the participant the need to use highly effective contraception consist ently and correctly according to 
contraception guidelines.
i. For postmenopausal (amenorrheic for at least 12 consecutive months) female participants only.
j. Urine drug (mandatory) and alcohol breath test (at discretion of investigator) will be performed at Screening and on Day -1. These tests may be performed 
at any other time at the discretion of the investigator.
k. Triplicate 12-lead ECG readings will be taken at specified times. All ECG assessments will be made after at least a 10-minute rest in a supine position and 
prior to any blood draws or vital sign measurements. ECG assessment should be taken in the morning with vitals. CCI
PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 18Visit Identifier
Abbreviations used in this table 
may be found in Appendix 9 .ScreeningaTreatment (See Detailed SoAs Below for Each Treatment) Follow-Up Early 
Termination/
Discontinuation
Days Relative to Day 1 of 
Period 1Day -28 to 
Day -2Day -1 Day 13 28-35 Daysb
Hours After Dose
l. Single supine BP, RR and PR will be performed following at least a 5-minute rest in a supine position. BP, RR and PR assessme nts will be performed after 
collection of ECGs and prior to collection of blood draws if scheduled at the same time.
m. Check exposure to positive participant, residence or travel in area of high incidence and COVID-19 related signs and symptoms.  To be done at Screening 
and no more than 48 hours before confinement to the CRU.
n. The testing for COVID-19 pathogen by RT-PCR will be performed at specified times while the participant is admitted for residen ce. For participants, a 
COVID-19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID-19 like s ymptoms.
o. To be done at least daily during residence. 
p. Please see the treatment tables below. 
q. Please see the PK sampling schedule tables below. PK samples should be collected at time of early termination/discontinuationr. Please see the Treatment 2 table below. 
 
C
C
I
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 19A.Treatment 1 (Single oral dose of dabigatran): Screening –Day 3
Visit Identifier
Abbreviations used in this table may be found in 
Appendix 9.Schedule for Treatm ent 1
Days Relative to Day 1 Day 1 Day 2 Day 3
Safety laboratory (including Fibrinogen)aX X
aPTT, PT-INR X X X
TSH & Free T4 X X
12-lead ECGbX X
Vital signs (BP/PR/RR/temperature)cX X
COVID -19 questionnaired
COVID -19 testingeX
COVID -19 check temperaturefX X X
Dabigatran administrationgX
PK blood sampling for dabigatran (total)hX X X
a.Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. All the safety laboratory 
samples must be collected follow ing at least a 4 hour fast. Additional safety laboratory assessments may be performed at any time at the discretion of the 
investigator. 
b.All ECG assessments (triplicate) will be made after at least a 10 -minute rest in a supine position and prior to any blood draw s or vital sign measurements.
ECG assessment should be taken in the morning with vitals.
c.Single supine blood pressure and pulse rate will be performed follow ing at least a 5 -minute rest in a supine position. BP and PR assessments will be 
performed after collection of ECGs and prior to collection of blood draw s if scheduled at the same time. RR will also be evaluated. Vitals should be taken in 
the morning with ECG assessments .
d.Check exposure to positive participant, residence or travel in area of high incidence and COVID -19 related signs and symptoms. To be done at Screening 
and no more tha n48hours before confinement to the CRU.
e.The testing for COVID -19 pathogen by RT -PCR or rapid testing via Abbott ID will beperformed at specified times while the participant is admitted for 
resid ence. For participants, a COVID -19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID -19 
like symptoms.
f.To be done at least daily during residence.
g.Dabigatran will be administered orally as a single dose. Dabigatran should be administered in the fasting condition (no food or drink except w ater).
h.One (approximately 4 mL) blood sample for PK analysis of dabigatran ( total) will be taken at the following timepoints: Day 1 pre -dose, and at 1, 2, 4, 6, 8, 
12, 16, 24, 36 and 48 hours post -dose.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 20Treatment 1 (Single oral dose of dabigatran): PK Sampling Schedule (Day s 1-3)
Visit IdentifierTreatm ent 1 on PK Days
Study DayDay 1 Day 2 Day 3
Planned Hours Post Morning Dose0a1 2 4 6 8 12 16 24 36 48
Study intervention administration X
PK blood sampling for dabigatran 
(total)X X X X X X X X X X X
12-lead ECG X X X
Vital Signs (BP/PR/RR/Temp erature ) X X X
a.Predose sample collection .

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 21B. Treatment 2 (PF-07321332/ritonav ir with dabigatran): Days 1-4
Visit Identifier
Abbreviations used in this table may be found in Appendix 9 .Schedule for Treatment 2
Days Relative to Day 1 Day 1 Day 2 Day 3 Day 4
Safety laboratory (including Fibrinogen)aXX
TSH & Free T4 X X
aPTT, PT-INR X X X
12-lead ECGbXX
Vital signs (BP/PR/RR/temperature) X X
COVID-19 testingcX
COVID-19 check temperaturedXX X X
Dabigatran administrationeX
PF-07321332/ritonavir administrationeX (am/pm) X (am only)
PK Blood Sampling for dabigatran (total)fXX X
PK Blood Sam pling for PF- 07321332 and ritonavirgX
Blood/plasma ratio sampleiX
a. Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. All the safety laboratory samples must be 
collected following at least a 4 hour fast. Additional safety laboratory assessments may be performed at any time at the discret ion of the investigator. 
b. All ECG assessments (triplicate) will be made after at least a 10-minute rest in a supine position and prior to any blood dra ws or vital sign measurements. ECG assessments 
should be taken in the morning with vital signs.
c. The testing for COVID-19 pathogen by RT-PCR or rapid testing via Abbott ID will be performed at specified times while the parti cipant is admitted for residence. For 
participants, a COVID-19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop  COVID-19 like symptoms.
d. To be done at least daily during residence.
e. On the morning of Day 2 (T2), dabigatran will be administered orally as a single dose. Dabigatran should be administered in the  fasting condition (no food or drink except 
water). On T2 Day 1 and Day 2 following an approximately 8-10-hour fasting period, PF-07321332/ritonavir 300 mg/ 100 mg will be c o-administered q12h as multiple doses
in the fasting condition.
f. One (approximately 4 mL) blood sample for PK analysis of dabigatran (total) will be taken at the following timepoints: Treatment  2 Day 2 (Study Day 6) pre-dose, and at 1, 
2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose.
g. One (approximately 4 mL) blood sample for PK analysis of PF-07321332 and ritonavir will be taken at the following timepoints: T reatment 2 Day 2 (Study Day 6) pre-dose, 
and at 1, 2, 4, 6, 8, 12 hours post-dose. 
i. Whole blood sample/aliquot (approximately 150 μL) for in vivo blood/plasma ratio assessment.CCI
C
C
PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 22Treatment 2 (PF-07321332/ritonavir with dabigatran): PK Sampling Schedule (Days 1-4)
Visit IdentifierTreatment 2 on PK Days
Day 1 Day 2 Day 3 Day 4
Planned Hours Post Morning 
Dose0a1 2 4 6 812 16 0a1 2 4 6 8 12 16 24 36 48
PF-07321332/ritonavir
administrationXX X
Dabigatran administration X
PK blood sampling for 
PF-07321332/ritonavirXXXXXXX
PK blood sampling for 
dabigatran (total)XXXXXXXX X X X
12-lead ECG X X X X
Vital Signs 
(BP/PR/RR/Tem perature )XX X X
 
Blood/Plasma ratio samplecX
a. Pre-dose sample
c. Whole blood sample/aliquot (approximately 150 μL) for in vivo blood/plasma ratio assessment.CCI
C
C
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 23C.Treatment 3 (Ritonavir with dabigatran): Day s 1-4
Visit Identifier
Abbreviations used in this table may be found in 
Appendix 9.Schedule for Treatm ent 3
Days Relative to Day 1 Day 1 Day 2 Day 3 Day 4
Safety laboratory (including Fibrinogen)aX X
aPTT, PT-INR X X X X
TS4 & Free T4 X X
12-lead ECGbX X
Vital signs (BP/PR/RR/temperature)cX X X
COVID -19 testingdX
COVID -19 check temperatureeX X X X
Dabigatran administrationfX
Ritonavir administrationgX (am/pm) X (am only)
PK blood sampling for dabigatran (total)hX X X
a.Safety laboratory assessments including urinalysis, hematology, and chemistry will be performed at the indicated timepoints. All the safety laboratory 
samples must be collected follow ing at least a 4 hour fast. Additional safety laboratory assessments may be performed at any time at the discretion of the 
investigator.
b.All ECG assessments (triplicate) will be made after at least a 10 -minute rest in a supi ne position and prior to any blood draw s or vital sign measurements.
ECG assessments should be taken in the morning with vitals .
c.Single supine BPand PRwill be performed following at least a 5 -minute rest in a supine position. BP and PR assessments will be performed after collection 
of ECGs and prior to collection of blood draw s if scheduled at the same time. RR will also be evaluated. Vitals should be taken in the morning with ECG 
assessments .
d.The testing for COVID -19 pathogen by RT -PCR or rapid testing via Abbott ID will be performed at specified times while the participant is admitted for 
residence. For participants, a COVID -19 test will be performed after 4 days (ie, upon completion of 4 × 24 hours in house), or if they develop COVID- 19 
like symptoms.
e.To be done at least daily during residence.
f.Dabigatran will be administered orally as a single dose. Dabigatran should be administered in the fasting condition (no food or drink except w ater).
g.In T3 Day 1 and Day 2, participants will rec eive multiple dosing of ritonavir 100 mg q12h the fasting condition over a period of 2 days.
h.One (approximately 4 mL) blood sample for PK analysis of dabigatran (total) will be taken at the following timepoints in T 3: Day 2 pre -dose, and at 1, 2, 4, 
6, 8, 12, 16, 24, 36 and 48 hours post -dose.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 24Treatment 3 (Ritonavir with dabigatran): PK Sampling Schedule (Days 1 -4)
Visit IdentifierTreatm ent 3 on PK Days
Day 1 Day 2 Day 3 Day 4
Planned Hours Post 
Morning Dose0a1 2 4 6 8 12 16 0a1 2 4 6 8 12 16 24 36 48
Ritonavir administration X X X
Dabigatran administration X
PK blood sampling for 
dabigatran (total)X X X X X X X X X X X
12-lead ECG X X X X
Vital Signs 
(BP/PR/RR /temperature )X X X X
a.Pre-dose sample.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 252.INTRODUCTION
PF-07321332 is a potent and selective inhibitor of the SARS -CoV -2 3CL  protease that is 
currentl y being developed as an oral treatment of COVID -19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increa se plasma 
concentrations of PF- 07321332 to values that are anticipated to be efficacious. 
2.1.Study Rationale 
In vitro and in vivo metabolite profiling suggests that the primary  clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. I n a reaction phenot yping study using human 
liver microsomes in the presence of selective CYP inhibitors, CYP3A4 was predicted to be 
the major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF- 07321332. As 
such, in the FIH stud y, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF- 07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Prel iminary  PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/100 mg q12h suggest 
that the renal pathway  may  also play  a significant role in PF -07321332 excretion when 
co-administered with riton avir, with approximately  32.5% (PF ‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at stead y-state, and renal clearance ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively  metabolized, primarily  by CYP3A4.1
The DDI potential of PF- 07321332 was further evaluated using a static mechanistic model
using the projected C max for reversible inhibition or C av time-dependent inhibition in plasma,
intestinal lumen, enterocy tes, liver, and portal inlet (incorporating k p,uu and k a). Based on this
model, PF -07321332 has minimal risk to inhibit CYPs other than 3A4, UGTs and transport 
proteins: however, the potential remains to reversibly  and time -dependentl y inhibit CYP3A4 
and inhibit P -gp in humans at the proposed therapeutic dose. 
Dabigatran etexilate (herein referred to as dabigatran) is a sensitive probe substrate of the 
efflux tran sporter P -gp that experiences a ≥2-fold increase in exposure upon coadministration 
with P -gp inhibitors verapamil or quinidine.2  Additionally , dabigatran is primarily  renall y 
eliminated by  glomerular filtration ( approximately 80%).2
Ritonavir is classified as a P -gp inhibitor. Although lim ited clinical data exists on drug -drug 
interactions with ritonavir and P
-gp probe substrates like dabigatran, results from one stud y 
assessing the concomitant administration of dabigatran etexilate and ritonavir did not result 
in statistically  significant changes in an y of the PK parameters of dabigatran or changes in 
thrombin time measures as compared to dabigatran administered alone. However, there was 
statistically  significant and similar decreases in the dabigatran AUC and C maxwhen 
dabigatran and riton avir were administered separately  by 2 hours compared to values 
obtained when dabigatran was administered alone, suggesting there may  be the potential of 
ritonavir to induce P -gp. Even though dabigatran is primarily  renall y eliminated, results 
suggested th at whether dabigatran and ritonavir were administered simultaneously  or 
separated b y 2 hours, there was no change in dabigatran t½or K elcompared to dabigatran 
administered alone.2

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 26Based on available data to date, it is possible that administration of a P -gp substrate , 
dabigatran with PF ‑07321332/ritonavir may  lead to further changes in exposures of 
dabigatran.3Therefore, results of this study  will provide guidance for dosing with substrates 
of P-gp.
The purpose of t his study is to estimate the effect of PF -07321332/ritonavir and ritonavir on 
the PK of dabigatran in healthy  participants.
2.2.Background 
In December 2019, COVID -19 was identified as a new, potentially  fatal, respiratory  infection 
caused b y the novel coronavirus, SARS -CoV -2. The WHO declared COVID -
19 a Public 
Health Emergency  of Internationa l Concern on 20 January 2020 and further characterized the 
disease outbreak as a pandemic on 11 March 2020.5
PF-07321332 is an orall y bioavailable 3C Lproinhibitor shown to be effective against 
SARS -CoV -2 3CLpro(Ki = 0.00311 µM) in a biochemical enzy matic assay . Since the 
3CLprofrom human coronaviruses are structurally similar and share a high degree of 
conservation at the active site of the enzy me, the ability  of PF -07321332 to inhibit the 3C Lpro 
of other coronaviruses (SARS- CoV -1 and H coV- 229E, MERS, H coV- OC43, H coV- HKU1, 
and H coV- NL63) was also confirmed, indicating a potential for broad spectrum anti -
coronavirus activity . The coronavirus 3CL protease is a virall y encoded enzyme that is 
critical to the SARS- CoV -2 replication cy cle, analogous to other o bligatory  virally  encoded 
proteases (eg, HIV Protease, HCV Protease).6PF-07321332 is being developed as an oral 
treatment in patients with COVID -19 infection. 
Ritonavir is a strong CYP3A4 inhibitor being used to inhibit the metabolism of PF -07321332 
in order to increase plasma concentrations of PF -07321332 to values that are anticipated to 
be efficacious. Ritonavir is not expected to have any  pharmacological impact on the 
SARS -CoV -2 virus. Ritonavir is being used only as a pharmacokinetic boosting agent.
2.2.1. Nonclinical Pharmacology
Details of the nonclinical pharmacology  of PF -07321332 can be found in the current IB.
2.2.2. Nonclinical Pharmacokinetics and Metabolism
Hepatic CYP3450 enzy mes were identified as the main pathway  for clearance of 
PF-07321332 in vitro i n liver microsomes (mouse, rat, hamster, rabbit, monkey, and human), 
hepatocy tes (rat, monkey, and human), and in vivo in rat and monkey  after repeat oral dosing 
(Study PF-07321332_09Nov20_084546). In a reaction phenoty ping study  using human liver 
microsom es in the presence of selective CYP inhibitors, CYP3A4 was predicted to be the 
major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF -07321332. No 
significant CYP3A5 contribution is expected to the metabolism of PF -07321332. 
(Study PF-07321332_21Nov20_072016 ). Urinary excretion of PF - 07321332 following 
single IV or oral doses in rats was approximately  11%, suggesting minor urinary  
contributions to the overall elimination of PF-07321332. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 27Additional information of the nonclinical PKand met abolism of PF -07321332 is available in 
the current IB.
2.2.3. Nonclinical Safety
There were no adverse findings observed in repeat- dose toxicity  studies in rats and monkey s 
up to 2 weeks duration and the NOAELs were the highest dose administered (1000 mg/kg 
and 7 5mg/kg in the rat and monkey  studies, respectively ). PF-07321332-related 
non-adverse, test article -related clinical findings included sporadic occurrence of emesis with 
slight body  weight decreases in monkey s. Monitorable and reversible clinical pathology
findings included those possibly
 suggestive of low -grade inflammation (in rats and monkey s) 
or alterations in the coagulation pathway s (in rats only ) without clinical or microscopic 
correlates. Other non -adverse clinical pathology  findings were likel y due to the emesis and 
subsequent deh ydration in monkeys. In rats administered 1000 mg/kg/day , lower mean 
absolute and relative heart weights (females) and higher absolute and relative liver weights 
(both sexes) were observed relative to controls. The lower heart weights had no microscopic 
correlates and were fully reversed at the end of the 2- week recovery  period. Higher liver 
weights correlated with reversible, non-adverse microscopic findings of minimal to mild 
severit y in the liver and thyroid gland consist ent with adaptive changes related to microsomal 
enzy me induction.
PF-07321332 was not mutagenic or clastogenic in in vitro genetic toxicity studies and 
was negative in the in vivo rat micronucleus assay  incorporated into the GLP 
repeat -dose rat toxicity  study. 
The nonclinical studies performed adequatel ysupport the oral administration of 
PF-07321332 in the clinic for up to 14 day s.
Further details of the nonclinical safet y program are provided in the current IB.
2.2.4.
Clinical Overview
Safety , tolerability  and pharmacokinetics of PF -07321332 in healthy  adult participants is 
currentl y being explored in an ongoing Phase 1 FIH study (C4671001). Prior to 
Amendment 3, Study  C4671001 is a 4- part stud y consisting of SAD (PART- 1), MAD 
(PART -2), relative bioavailability /food effect (PART3), and metabolism and excretion study  
(PART -4). PART- 1 and -2 are randomized, double- blind, sponsor -open, and placebo 
controlled to evaluate safety , tolerability , and PK of single and multiple escalating oral doses 
of PF -07321332, respectively. PART -3 is randomized and open -label to evaluate relative 
bioavailability  and food effect of an oral tablet formulation. PART -4 is an open- label, 
non-randomized, single period to evaluate the metabolism and excretion of PF - 07321332. 
Included in this Clinical Overview are summaries of the preliminary  results from PART-1 
and PART -2. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 282.2.4.1. Safety Overview
Preliminary  safet y and tolerability data from Study C4671001 as of 07 April 2021 in PART -1 
and 14 April 2021 in PART -2 (data snapshot taken) demonstrated PF -07321332 was 
generall y safe and well -tolerated in healthy  participants at single doses of PF -07321332 
ranging from 150 mg to 1500 mg alone and at 250 mg and 750 mg with ritonavir (100 mg at 
-12h, 0h, 12h) in the PART -1: SAD, and 10 day s ofdosing from 75 mg BID to 500 mg BID 
with 100 mg ritonavir BID in the PART -2: MAD of the study . 
Following single doses of PF
-07321332 with and without ritonavir, all AEs were mild and 
none was considered treatment related. There were no obvious trends in, or association of, 
TEAEs with an y dose level of PF -07321332. Following multiple doses, the most commonly  
observed AEs b y system organ class were gastrointestinal disorders and nervous sy stem 
disorders. Diarrhea was the most common reported AE, occurring i n 4participants across 
treatment groups. A total of 5 treatment related TEAEs were observed in Part- 2: MAD. 
Across treatment groups, blood TSH increased in 3 participants, and 2 participants reported 
dysgeusia. The 3 participants with elevated TSH results did not experience related clinical 
symptoms and the free T4 results remained within reference range. 
Based on review of preliminary  (unaudited) data, all reported adverse events have been of 
mild intensity . There have been no deaths, serious adverse eve nts, or SUSARs reported. 
There were no clinicall y meaningful findings in vital signs, ECG, or potential Hy ’s Law 
cases reported during this study . 
Further details on the clinical safety information with PF -07321332 are provided in the 
current IB.
2.2.4.2. Summary of PF -07321332 Pharmacokinetics in Human
Preliminary  single dose PK data from Study C4671001 at doses of PF -07321332 of 150 mg, 
500mg, and 1500 mg alone and at 250 mg and 750 mg with ritonavir 100 mg (dosed at -12h, 
0h, and 12h) show that PF -07321332 was absorbed rapidly  with median T maxof 1hour or 
less when administered alone and 2.75
hours or less when administered with ritonavir. Since 
PF-07321332 is primarily  metabolized by  CYP3A4 and ritonavir is a CYP3A4 inhibitor, 
dosing with ritonavir increased t he exposure of PF -07321332. Highest observed mean C max
and AUC lastwas 5.09 µg/mL  and 64.26 µg.h/mL, respectivel y, at 750 mg PF-07321332 
dosed with ritonavir. The mean half -life of PF -07321332 was approximately  2hours when 
administered alone and increased to approximately  6-
13hours when co- administered with 
ritonavir. Dosing with a high -fat meal modestl y increased the exposure of PF -07321332 
(approximately  15% increase in mean C maxand 1.6% in mean AUC last). 
Preliminary  PK data on Day 1, Day  5 and Day 10 following multiple oral administration of 
PF-07321332/ritonavir 75/100 mg, 250/100 mg, and 500/100 mg BID suggest less than 
proportional increase in exposures at steady  state. Multiple dosing over 10 days achieved 
steady  state on Day  2 with approximately  2-fold accumulation. Day  5 and Day  10 exposure 
was similar at all doses. Approximately  32.5% to 64.6% of the drug was excreted unchanged 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 29in urine across different doses at stead y-state. The renal clearance ranged between 3.5 to 
4.4L/h across doses.
Furthe r details on the clinical PK of PF -07321332 are provided in the current IB.
2.3.Benefit/Risk Assessment
PF-07321332/ritonavir alone or in combination with dabigatran is not expected to 
provide an y clinical benefit to healthy participants in this study . This st udy is 
designed primaril y to generate safet y, tolerability , and pharmacokinetic data for 
further clinical development. 
Based on preliminary  data from the ongoing Phase 1 study  (C4671001) collected as 
of 07 April 2021 in PART -1 and 14 April 2021 in PART-2 (data snapshot taken), the 
clinical safet y profile of PF -07321332 appears to be acceptable at single doses up to 
1500 mg alone and up to 750 mg administered with ritonavir (100 mg 
at -12h, 0h, 12h), and at repeated daily  doses administered orall y for 10 da ys of up to 
500mg PF -07321332 BID with 100 mg ritonavir BID. 
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of PF -07321332 may  be found in the IB, which is the SRSD for this study . The 
SRSDs for rito
navir7and dabigatran8are the corresponding USPI s. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 302.3.1. Risk Assessment
Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s): PF-07321332
Emesis Sporadic emesis wasobserved at ≥100 mg/kg/day of 
PF-07321332 in the 15 -day NHP -toxicology study (See IB). 
Based on preliminary data, no emesis was observed in the 
FIH Study C4671001 at single doses of PF -07321332 up to 
1500 m g alone and up to 750 mg administered with riton avir 
(100 mg at -12h, 0h,12h), and at repeated daily doses 
administered orally for 10 days of up to 500 mg 
PF-07321332 BID with 100 mg ritonavir BID.As this is an investigational agent, there is some 
risk that is mitigated by close observation of AEs, 
etc. If needed, palliative care or antiemetics may 
be provided.
Neuronal and pulmonary effects Transient effect in rat neuronal and pulmonary endpoints 
were observed in rat toxicology study at the high dose level 
(1000 mg/kg as single dose; See IB). Based o n preliminary 
data, no AEs suggestive of neuronal or pulmonary effects 
were observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h,12h), and at 
repeated daily doses administered orally for 10 days of up to 
500mg PF -07321332 BID with 100 mg ritonavir BID.Vital signs, including respiratory rate, will be 
monitored for pulmonary effect. There w ill be 
close observation of AEs for any signs of 
neuronal effect. 
Hem odynamic effects Low level inflammation (increase in fibrinogen) in 15 -day 
NHP toxicology study and changes in platelets, globulin and 
albumin/globulin ratio and coagulation system (increase in 
PT and aPTT) in 14 -day rat toxicology study (See IB). No 
relev ant laboratory changes in inflammatory markers have 
been observed in the FIH Study C4671001 at single doses of 
PF-07321332 up to 1500 mg alone and up to 750 mg 
administered with ritonavir (100 mg at -12h, 0h,12h), and at 
repeated daily doses administered orally for 10 days of up to 
500mg PF -07321332 BID with 100 mg ritonavir BID.Fibrinogen, platelets, PT -INR and aPTT, albumin 
and total proteins will be monitored. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 31Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Thyroid function studies In 14 -day rat toxicology study at high dose of PF -07321332 
(1000 mg/kg/day) thyroid gland changes observed w ere of 
low severity and without evidence of tissue damage. In the 
FIH Study C4671001, 3 participants had TEAEs of elevated 
TSH levels across treatment groups (PF -07321332 or 
placebo w ith ritonavir 100 mg BID) in t he MAD part of the 
study. There was no clinical correlation w ith these TSH 
changes and free T4 remained w ithin reference range at all 
times.TSH and free T4 will be evaluated to monitor 
thyroid function
Study Intervention(s): Ritonavir
Gastrointestinal disturbances (including 
diarrhea, nausea, vomiting and 
abdominal pain).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose of 100 mg twice daily is used in this 
study. There will be close observation of AEs. If 
needed, anti -emetics may be provided. 
Neurological disturbances (eg, 
paresthesia, including oral paresthesia, 
dysgeusia and dizziness).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs. 
Rash (most commonly reported as 
erythematous and maculopapular, 
followed by pruritic).Frequently reported adverse reaction in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physical exams. If needed, palliative care 
may be provided. 
Fatigue/Asthenia Frequently reported adverse reactio n in HIV patients at 
600mg BID.Lower dose used in this study. There w ill be close 
observation of AEs and monitoring through 
targeted physical exams.
Limited case reports of renal toxicity Although ritonavir therapy is not generally considered 
nephrotoxic, a limited number of cases of acute kidney 
injury secondary to ritonavir have been reported post -
marketing in HIV patients.Lower dose used in this study. There w ill be close 
observation of AEs and renal function.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 32Potential Risk of Clinical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention (s): Dabig atran
Spinal/Epidural hematoma: When spinal/epidural anesthesia or spinal puncture is 
employed patients treated w ith anticoagulant agents are at 
risk of developing an epidural or spinal hematoma.Participants are excluded who have had neuraxial 
anesthesia or have undergone spinal puncture
Bleeding which can be serious, and 
sometimes lead to death. This is because 
PRADAXA ®is a blood thinner 
medicine that lowers the chance of 
blood clots forming in your body.Dabigatran increases the risk of bleeding and can cause 
significant and, sometimes, fatal bleeding. Promptly evaluate 
any signs or symptoms of blood loss (eg, a drop i n 
hemoglobin and/or hematocrit or hypotension).Measurement of PT, aPTT, INR th roughout all 
3treatments in the study. In addition, CBC to 
monitor platelets, H gb,HCT, etc. as w ell as 
hemodynamic monitoring such as BPand PRare 
also being evaluated in the study.

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 332.3.2. Benefit Assessment
PF-07321332/ritonavir and dabigatran will not provide any clinical benefit to healthy 
participants in this study. Any anticipated benefit to participants would be in terms of contribution to the process of developing a new therapy in an area of unmet medical need.
2.3.3. Overall Benefit/Risk Conclusion
PF-07321332/ritonavir and dabigatran are not expected to provide any clinical benefit to 
healthy participants in this study. Taking into account the measures taken to minimize risk to participants of this study, the potential risks identified in association with administration of PF-07321332/ritonavir and dabigatran are justified by the anticipated benefit, in terms of contribution to the process of developing a new therapy in an area of unmet medical need.
3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints
Primary: Primary:
•To estimate the effect of the multiple doses of 
PF-07321332/ritonavir co-administered with 
dabigatran orally (test) compared to dabigatran administered orally as a single dose (reference).•Plasma dabigatran (total) PK parameters: C
max,
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated).
Secondary: Secondary: 
•To estimate the effect of the multiple doses of 
ritonavir co-administered with dabigatran orally 
(test) compared to dabigatran administered 
orally as a single dose (reference).
•To evaluate the safety and tolerability of 
dabigatran alone and following co-administration with multiple dosing of 
PF-07321332/ritonavir or ritonavir
•To characterize the PK of dabigatran and 
PF-07321332 in study treatments.•Plasma dabigatran (total) PK parameters: C
max,
AUC inf(or AUC lastif AUC infcannot be reliably 
estimated).
•Safety: TEAEs, clinical laboratory tests, vital
signs, PE, and ECGs.
•Dabigatran (total): T max, t½, as data permit
•PF-07321332: C max, AUC tau, Tmax, t½, CL/F, 
Vz/F.
 
 
 
4. STUDY DESIGN
4.1. Overall Design
This is a Phase 1, open-label, randomized, 3-treatment, 6-sequence, 3-way crossover design 
to estimate the effect of PF-07321332/ritonavir or ritonavir on the PK of a P-gp substrate, dabigatran in healthy participants.CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 34This study  will consist of 3 treatments. In T1, dabigatran will be administered orall y as a 
75mg single dose followed by  a 3-day washout. In T2, PF -07321332/ritonavir 
300mg/100 mg q12h will be administered as a multiple dose over a period of 2 day s. In the 
morning on Day  2, 75 mg of dabigatran will be administered orally  as a single dose. 
Treatment 2 will be followed b y a 3 -day washout. In T3, ritonavir 100 mg q12 h will be 
administered as a multiple dose over a period of 2 day s. In the morning on Day  2, 75 mg of 
dabigatran will be administered orall y as a single dose. Each washout period will begin after 
the first dose of stud y treatment. A total of approximately  24healthy  male and/or female 
participants will be enrolled into the study . Participants who discontinue from the study  may  
be replaced at the sponsor’s discretion in collaboration with the I nvestigator. 
The purpose of 
this study is to estimate the effect of PF -07321332/ritonavir and ritonavir on 
the PK of dabigatran in healthy  participants.
Health y participants (approximately  n=24) will be screened to determine eligibility  within 28 
days prior to study  treatment. Medica l history  and results of PE, phy sical measurements, vital 
signs, 12 -lead ECGs, and clinical laboratory  evaluations will determine eligibility . 
Participants will report to the CRU at least 12 hours prior to Day 1 dosing in T1 and will be 
required to stay  inthe CRU for 13 days and 12 nights. Each washout period will begin after 
the first dose of stud y treatment.
Participants will randomly be assigned to 1 of 6 sequences as follows: 
Period 1 Period 2 Period 3
Sequence 1 Treatment 1 Treatment 2 Treatment 3
Sequence 2 Treatment 3 Treatment 1 Treatment 2
Sequence 3 Treatment 2 Treatment 3 Treatment 1
Sequence 4 Treatment 3 Treatment 2 Treatment 1
Sequence 5 Treatment 2 Treatment 1 Treatment 3
Sequence 6 Treatment 1 Treatment 3 Treatment 2
The following describes the study  design as an example for Sequence 1 (T1 -T2-T3):
Participants in T1 (Day  1) will receive dabigatran orally  administered as a 75 mg dose 
followed b y a 3 -day washout. Serial PK samples will be collected up to 48 hours after single 
dose administration to determine PK parameters. 
T2 will begin on Study  Day  5 (referred to as T2 Day 1). Participants in T2 (Day  1) will 
receive multiple doses of PF -07321332/ritonavir 300 mg/100 mg q12h on Day s 1 and 2 
followed b ya single dose of 75 mg dabigatran administered orally  on Day  2. A 3 -day 
washout will ensue the co- administration of PF -07321332/ritonavir and dabigatran. Serial PK 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 35samples will be collected up to 48 hours following the administration of 
PF-07321332/ritona vir co -administered with a single oral dose of 75 mg dabigatran. 
T3 will begin on Study  Day  10 (referred to as T3 Day  1). Partic ipants in T3 (Day  1) will 
receive multiple dose administration of ritonavir 100 mg q12h on Day s 1 and 2. In the 
morning on Day  2, participants will be administered a single oral 75 mg dose of dabigatran. 
Serial PK samples will be collected up to 48 hours following multiple dose administration of 
ritonavir 100 mg co -administered with a single oral dose of 75 mg dabigatran. 
The tot al planned duration of participation, from the Screening visit to the last Follow -
up 
phone call, is approximately  11 weeks.
Eligible participants will be admitted to the CRU on Day  -1 (at least 12 hours prior to Day 1 
dosing of dabigatran dosing on Day 1) and will be confined in the CRU for 13 days and 
12nights. On the morning of Day 1 (T1), the participants will receive a single oral dose of 
75mg of dabigatran administered orall y, followed by a 3 -day washout. Serial blood samples 
at specified intervals w ill be collected up to 48 hours post -dose for PK assessments . On the 
morning of Day  1 and Day  2 in T2, PF -
07321332/ritonavir 300 mg/100 mg will be 
administered as multiple doses q12h. Dabigatran 75 mg will be administered orally , as a 
single dose on Day  2.On the morning of Day  1 and Day  2 in T3 participants will receive 
multiple dosing of ritonavir 100 mg q12h. On Day  2 of T3, participants will receive 
administration of a single oral dose of 75 mg dabigatran .Serial blood samples at specified 
intervals wil l be collected up to 48 hours post -dose for PK assessments of both ritonavir and 
dabigatran. Each washout period will begin after the first dose of study  treatment.
All study  treatments, regardless of dosing regimen should be administered in the fasting 
condition. Specifically , morning doses should be followed by  an overnight fast of 
approximately  8-10 hours. When PK is performed after the morning dose, a 4 -hour fast 
should occur. Evening dose will be administered 1 hour before or 2 hours after a meal.   
Safety  assessments will be performed during Screening, on Day  -1 prior to dosing, and at 
specified time points. PE s, vital sign measurements, and clinical laboratory  tests will be 
conducted, and AEs will be monitored to assess safety . The total participati on time (eg, CRU 
confinement time for study  procedures) for each participant in this study  is approximately  
13days/12 nights (excluding screening and follow -up contact). Participants will be 
discharged in T3, Study  Day 13 following completion of all asses sments.
A safet y follow- up call will be made to participants approximately  28 to 35 day s from 
administration of the final dose of study  intervention.
4.2.Scientific Rationale for Study Design
PF-07321332 is a potent and selective inhibitor of the SARS -CoV -2 3C L protease that is 
currentl y being developed as an oral treatment of COVID -19. Ritonavir is a strong CYP3A4 
inhibitor being used to inhibit the metabolism of PF -07321332 in order to increase plasma 
concentrations of PF-07321332 to values that are anticipat ed to be efficacious. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 36In vitro and in vivo metabolite profiling suggests that the primary  clearance mechanism for 
PF-07321332 is CYP3A4 mediated oxidation. I n a reaction phenot yping study using human 
liver microsomes in the presence of selective CYP inhib itors, CYP3A4 was predicted to be 
the major contributor (f m= 0.99) to the in vitro oxidative metabolism of PF- 07321332. As 
such, in the FIH stud y, C4671001, the CYP3A4 inhibitor ritonavir was used to enhance the 
exposure of PF- 07321332 in order to achieve plasma levels that are anticipated to be 
efficacious. Preliminary  PK data following multiple oral administrations of 
PF‑07321332/ritonavir at doses of 75/100 mg, 250/100 mg, and 500/100 mg q12h suggest 
that the renal pathway  may  also play  a significant role in PF -07321332 excretion when 
co-administered with ritonavir, with approximately  32.5% (PF ‑07321332/ritonavir 
500/100 mg) to 64.6% (PF‑07321332/ritonavir 75/100 mg) of the drug excreted unchanged 
in urine across doses at stead y-state, and renal clearanc e ranging between 3.5 to 4.4 L/h 
across doses. Ritonavir is extensively  metabolized, primarily  by CYP3A4.1
The DDI potential of PF- 07321332 was further evaluated usi ng a static mechanistic model
using the projected C max for reversible inhibition or C av time-dependent inhibition in plasma,
intestinal lumen, enterocy tes, liver, and portal inlet (incorporating k p,uu and k a). Based on this
model, PF -07321332 has minimal risk to inhibit CYPs other than 3A4, UGTs and transport 
proteins; however, the potential remains to reversibly  and time -dependentl y inhibit CYP3A4 
and inhibit P -gp in humans at the proposed therapeutic dose. 
Dabigatran is asensitive probe substrate of the efflux transporter P-gp that experiences a ≥ 2-
fold increase in exposure upon coadministration with P- gp inhibi tors verapamil or quinidine.2
Additionally , dabig atran is primarily renall y eliminated b y glomerular filtration 
(approximately  80%).2
Ritonavir is classified as a P-gp inhibitor. Although limited clinical data exists on drug -drug 
interactions with ritonavir and P
-gp probe substrates like dabigatran, results from one stud y 
assessing the concomitant administration of dabigatran etexilate and ritonavir did not result 
in statistically  significant changes in an y of the PK parameters of dabigatran or changes in 
thrombin time measures as compared to dabigatran administered alone . However, there was 
statistically  significant and similar decreases in the dabigatran AUC and C maxwhen 
dabigatran and ritonavir were administered separately  by 2 hours compared to values 
obtained when dabigatran was administered alone , suggesting there may be the potential of 
ritonavir to induce P -gp. Even though dabigatran is primarily  renall y eliminated, results 
suggested that whether dabigatran and ritonavir were administered simultaneously  or 
separated b y 2 hours, there was no change in dabigatran t½or K elcompared to dabigatran 
administered alone.2
Based on available data to date, it is possible that administration of a P -gp substrate , 
dabigatran with PF ‑07321332/ritonavir may  lead to changes in exposures of dabigatran .3
Therefore, results of this study  will provide guidance for dosing with substrates of P-gp.
Lastl y, the rationale to study  the effect of ritonavir on dabigatran is for labeling purposes.
Pfizer is pursuing the goal of a label similar to ritonavir with respect to DDI s. If the results 
from this study  suggest that there is no influence of ritonav ir on dabigatran concentrations as 

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 37compared to PF-07321332/ritonavir, this may be a convincing argument to not pursue 
additional DDI studies and accept the ritonavir label.  
4.2.1. Choice of Contraception/Barrier Requirements 
Human reproductive safety data are limited for PF-07321332, but there is no suspicion of 
human teratogenicity based on the intended pharmacology of the compound. Therefore, the use of a highly effective method of contraception is required (see Appendix 4 ).
 
4.3. Justification for Dose
A dose of 300 mg PF-07321332, pharmacokinetically enhanced with 100 mg ritonavir, to be 
administered as a single dose is planned in this study. This is the anticipated Phase 2/3 dose of PF-07321332/ritonavir of 300/100 mg.
When co-administered with ritonavir, doses of PF-07321332 up to 750 mg single dose and 
500 mg q12h for 10 days were generally safe and well tolerated based on preliminary data form the Phase 1 Study C4671001. There have been no deaths or serious adverse events or SUSARs reported. Based on review of preliminary (unaudited) data, all reported adverse events have been of mild intensity. There were no clinically meaningful findings in vital signs, ECG, or potential Hy’s Law cases reported during the study. 
The dose of ritonavir to be used in this study is 100 mg administered in combination with 
PF-07321332. This dose is the typical dose of ritonavir when used as a PK enhancer. 
Little research is available to date utilizing dabigatran as a P-gp substrate. Some DDI studies 
available in the published literature utilize a 150 mg single oral dose when using dabigatran as a P-gp probe.
3As increases in dabigatran exposure may occur when co-administered with 
PF-07321332/ritonavir or ritonavir alone a single oral dose of 75 mg of dabigatran was chosen for this study. 
4.4. End of Study Definition
The end of the study is defined as the date of last scheduled procedure shown in the SoA for 
the last participant in the trial.
A participant is considered to have completed the study if he/she has completed all parts of 
the study, including the last scheduled procedure shown in the SoA.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The 
following eligibility criteria are designed to select participants for whom participation in the study is considered appropriate. All relevant medical and nonmedical conditions should be CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 38taken into consideration when deciding whether a particular participant is suitable for this 
protocol. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex:
1.Male or female participants must be 18 to 60 y ears of age, inclusive, at the time of 
signing the ICD.
Type of Participant and Disease Characteristics:
2.Male and female participants who are overtl y healthy as determined b y medical 
evaluation including medical history , PE, laboratory  tests, and cardiac monitoring.
Refer to Appendix 4forreproductive criteria for male ( Section 10.4.1 ) and 
female ( Section 10.4.2) participants
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests, and other 
study  procedures.
4.Female participates of childbearing potential must have a negative pregnancy  test.
Weight: 
5.BMI of 17.5 to 30.5 kg/m2; and a total body  weight >50 kg (110 lb). 
Informed Consent:
6. Capable of giving signed informed consent as described in Appendix 1 , which 
includes compliance with the requirements and restrictions listed in the I CD and in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Positive test result for SARS -CoV -2 infection at the time of Screening or Day  -1.
2.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy chiatric, neurological, o
r 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 39allergic disease (including drug allergies, but excluding untreated, as ymptomatic, 
seasonal allergies at the time of dosing).
3.Any history  of malignancy  (with the exception of adequatel y treated or excised 
non-metastatic basal cell or squamous cell carcin oma of the skin or cervical 
carcinoma in situ).
4.Clinically relevant abnormalities requiring treatment (eg, acute my ocardial infarction, 
serious tach y
-or brady -arrhy thmias) or indicating serious underl ying heart disease 
(eg,prolonged PR interval, cardiom yopath y, underlying structural heart disease, 
Wolff Parkinson –White syndrome). 
5.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y)
6.History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HbsAb, 
H
bsAg, H bcAb, or HCVAb. Hepatitis B vaccination is allowed.
7.Any conduction abnormality  (including but not specific to left or right comple te 
bundle branch block, or AV block [2 nddegree or higher]).   
8. Having undergone neuraxial intervention or undergoing spinal puncture 12 weeks
prior to study  start or planned neuraxial intervention or spinal puncture within 12
weeks after the end of the stu dy.
9.Active pathological bleeding or risk of bleeding including prior personal or familiar 
history  of abnormal bleeding, hereditary  or acquired coagulation or platelet disorder 
or abnormal coagulation test (PT/I NR or PTT/aPTT greater than upper limit of 
normal) result at screening. 
10.Mechanical prosthetic heart valve surgery . 
11.Other medical or psy chiatric condition including recent (within the past y
ear) or 
active suicidal ideation/behavior or laboratory  abnormality  or other conditions or 
situations related to COVID -19 pandemic (eg, Contact with positive case, residence, 
or travel to an area with high incidence) that may  increase the risk of study 
participation or, in the investigator’s judgment, make the participant inappropriate for 
the study .
Prior/Concomi tant Therapy:
12.Use of prescription or nonprescription drugs and dietary  and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. (Refer to Section 6.8 Concomitant Therap y for additional details).

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 4013.Current use of any prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to Section 10.8 (Appendix 8 ) 
Concomitant Therap y.
14. Participants who have been vaccinated with COVID-19 vaccines within the past week 
(7 day s) of dosing or are to be vaccinated with these vaccines at an y time during the 
study  confinement period.
Prior/Concurrent Clinical Study Experience:
15.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of study  intervention 
used in this study  (whichever is longer). Participants who have participated in 
previous clinical trials with PF -07321332 may  be eligible to participate in this study  
as long as they  meet all other criteria. 
Diagnostic Assessments:
16.A positive urine drug test.
17.Screening supine BP ≥140 mmHg (s ystolic) or ≥90mmHg (diastolic), following at 
least 5 minutes of supine rest. If BP is ≥140 mmHg (s ystolic) or ≥90mmHg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the participant’s eligibility .
18.Baseline 12-lead ECG (triplicate) thatdemonstrates clinically relevant abnormalities 
that may affect participant safety or interpretation of study results (eg, baseline QTcF 
interval >450 msec, complete LBBB, signs of an acute or indeterminate 
age-myocardial infarction, ST -T interval changes suggestive of my ocardial ischemia, 
second -or third -degreeAVblock, or serious brady arrhy thmias or tachy arrhy thmias). 
If the baseline uncorrected QT interval is >450 msec, this interval should be rate 
corrected -using the Fridericia method and the resulting QTcF should be used for 
decision making and reporting
.If QTcF exceeds 450 msec, or QRS exceeds 
120msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or 
QRS values should be used to determine the participant’s eligibility . Computer
interpreted
-ECGs should be overread b y a physician experienced in reading ECGs 
before excluding a participant.   
19. Participants with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study  specific -laboratory  and confirmed by  a single 
repeat test, if deemed ne cessary : 
AST or ALT level  1.0 × ULN;

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 41Total bilirubin level ≥1.5 ×ULN; participants with a history  of Gilbert ’s 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is ≤ ULN;
eGFR <90 mL/min /1.73m2(
-10%) based on the CKD -EPI equation .
Other Exclusions:
20.Active acute or chronic infection requiring treatment with oral/parenteral antibiotics, 
antivirals (including biologic treatments), antiparasitics, antiprotozoals, or 
antifungals.
21.Participants considered in imminent need for surgery  or with elective surgery  
scheduled to occur during the stud y.
22.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a p attern of 
5(male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, 
alcohol intake should not exceed 14 units per week (1 unit= 8 ounces [240 mL] beer, 
1ounce [30 mL] of 40% spirit or 3 ounces [90 mL] of wine).
23.Blood donation (excluding plasma donations) of approximately  1pint (500 mL) or 
more within 60 days prior to dosing.
24.History  of sensitivity  to heparin or heparin –induced thrombocy topenia.
25.Unwilling or unable to comply  with the criteria in the Lifesty le Considerations
section of this protocol.
26.Investigator site staff or Pfizer employ ees directl y involved in the conduct of the 
study , site staff otherwise supervised by  the investigator, and their respe ctive family  
members. 
27.History  of sensitivity  reactions to ritonavir or dabigatran or any  of the formulation 
components of PF -07321332, ritonavir, or dabigatran.
28.Women who are pregnant or breastfeeding or planning to become pregnant during the 
study  period.
29.For an y of the diagnostic tests/assessments, if a result is outside the normal limit, the 
principal investigator can make a decision in consult with the Pfizer medical monitor.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 425.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Vaccine and Exposure to Infections Guidelines
Participant-Specific Recommendations:
It is recommended that all participants should be up -to-date with respect to standard of care 
vaccinations as defined by their country  health ministry .
Guidance on Vaccinations:
Vaccination with live attenuated vaccine is prohibited within the 6 weeks prior to Day  1 
(Baseline), during the study , and until the last Follow up visit. Similarly , current routine 
household contact with individuals who have been vaccinated with live -attenuated vaccines 
should be avoided in the same period. This is due to the potential for virus to be shed in 
bodily  fluids (including stool) following vaccination with live vaccines, leading to a potential 
risk that the virus may  be transmitted. General guid elines for immunosuppressed subjects 
suggest that exposure (through routine contact) should be avoided following vaccination (of 
others) with these vaccines for the stated time period:
a.Varicella or attenuated typhoid fever vaccination for 4 weeks following vaccination.
b.Oral polio vaccination for 6 weeks following vaccination.
c.Attenuated rotavirus vaccine for 10 day s following vaccination.
d.FluMist (intranasal flu vaccine) for 1 week following vaccination.
Participants should avoid exposure to vaccinated or i nfected persons and contact the 
investigator promptl y if they develop signs or s ymptoms of any  infections.
If a participant is offered, in accordance with the prevailing local guidelines, a non -live 
COVID -19 vaccine, it is permitted during this study  and s hould be reported as a concomitant 
medication.
5.3.2. Meals and Dietary Restrictions
All study  treatments, regardless of dosing regimen should be administered in the 
fasting condition (no food and drink e xcept water) . Specifically, morning doses 
should be followe d by an overnight fast of approximately  8-10 hours. When PK is 
performed after the morning dose, a 4 -hour fast should occur. Evening dose will be 
administered 1 hour before or 2 hours after a meal.
On day s where no PK sampling is required, participants 
can resume normal intake of 
both food and water.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 43Noncaffeinated drinks (except grapefruit or grapefruit related -citrus fruit juices—see 
below) may  be consumed with meals and the evening snack.
Lunch can be provided approximately  4hours after dosing the l ast dose of the 
morning of either dabigatran or PF -07321332/ritonavir. 
Dinner can be provided approximately  2hours after dosing the last dose in the 
evening 
of either PF -07321332/ritonavir or ritonavir . 
An evening snack may  be permitted.
Participants wi ll refrain from consuming red wine, grapefruit, or grapefruit- related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of study  intervention until collection of the final PK blood sample. 
While participants ar e confined, their total daily nutritional composition should be 
approximately  55% carbohy drate, 30% fat, and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.3. Caffeine, Alcohol, and Tobacco
Participants will abstain from caffeine containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample of each study  period. 
Participants will abstain from alcohol for 24 hours prior to admission (except as 
stated above for red wine) to the CRU and continue abstaining from alcohol until 
collection of the final PK sample of each study  period. Participants may  undergo an 
alcohol breath test or blood alcohol test at the discretion of the investigator.
Participants will a bstain from the use of tobacco or nicotine containing products for 
24 hours prior to dosing and during confinement in the CRU. 
5.3.4. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at l east 48 hours prior to each blood collection for clinical 
laboratory  tests. Walking at a normal pace will be permitted.
5.3.5. Contraception 
The investigator or his or her designee, in consultation with the participant, will confirm that 
the participant has sele cted an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 ) and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the schedule of activities (SoA), the 
investigator or designee will inform the participant of the need to use highly  effective 
contraception consistently and correctly and document the conversation and the participant’s 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 44affirmation in the participant’s chart (participants need to affirm their consistent and correct 
use of at least 1 of the selected methods of contraception) considering that their risk for 
pregnancy  may  have changed since the last visit. In addition, the investigator or designee will 
instruct the participant to call immediately  if the selected contraception method is 
discontinued or if pregnancy  is known or suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen failure data are collected and remain as 
source and are not reported on the CRF.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened. 
6.STUDY INTERVEN TION(S) AND CONCOMITANT THERAPY
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, medical device(s), or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to PF -07321332/ritonavir and 
dabigatran.
6.1.Study Intervention(s) Administered
PF-07321332 100 mg tablets will be supplied by  Pfizer. Ritonavir 100 mg tablets and 
dabigatran 75 mg capsules will be supplied by  the CRU .
6.1.1. Administratio n
Investigational products will be administered orally  and according to the conditions 
described in the SoA section and Protocol Section 5.3.2 Meals and Dietary  Restrictions.
In T1, Day  1 participants will receive a single 75 mg dose of dabigatran administered orally
in the morning starting at approximately  0800 hours (plus or minus 2 hours). 
In T2, on Day s1 and 2, participants will receive 300 mg PF -07321332 administered orall y 
with 100 mg ritonavir at approximately  0800 hours (plus or minus 2 hours). PF -07321332 
and ritonavir should be administered no more than 5 minutes of each other. PF -07321332 and 
ritonavir will be administered q12h on Day s 1 (am and pm) and 2 (am only). On the morning 
of Day  2, a single oral dose of dabigatran 75 mg will be administered in combination with 
PF-07321332/ritonavir. Administration of dabigatran should occur at approximate ly 0815 to 
0830 hours (plus or minus 10 minutes) after administration of PF -07321332/ritonavir.
In T3, on Day s 1 and 2, participants will receive 100 mg ritonavir q12h at approximately  
0800 hours (plus or minus 2 hours)
. Ritonavir will be administered q12h on Day s 1 (am and 
pm) and 2 (am onl y). On the morning of Day  2, a single oral dose of 75 mg dabigatran will 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 45be administered in combination with ritonavir. Administration of dabigatran should occur at 
approximately  0815 to 0830 hours (plus or minus 10 minutes) after administration of 
ritonavir. 
Each washout period will begin after the first dose of study  treatment.
Investigator site personnel can administer water at ambient temperature in all Treatment 
periods. Study  intervention will be administered according to the IMP and the protocol.
All study  treatments, regardless of dosing regimen should be administered in the fasting 
condition ( nofood and drink except water). Specifically , morning doses should be followed 
by an overnight fast of approximately 8-10 hours. When PK is performed after the morning 
dose, a 4- hour fast should occur. Evening dose will be administered 1 hour before or 2 hours 
after a meal.   
6.2.Preparation, Handling, Storage, and Accountability
1.The investigator or designee must confirm ap propriate temperature conditions have 
been maintained during transit for all study  interventions received and any  
discrepancies are reported and resolved before use of the study  intervention. 
2.Only  participants enrolled in the study  may  receive study  inter vention and only  
authorized site staff may  supply  or administer study  intervention. All study  
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimu m and maximum temperatures since previousl y documented for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to Pfizer upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until Pfizer provid es permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the I P manual.
4.Any storage conditions stated in the SRSD will be superseded b y the storage 
conditions stated on the label.
5.Study  interventions should be stored in their original containers.
6.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention ac countability , reconciliation, and record 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 46maintenance (ie, receipt, reconciliation, and final disposition records), such as the 
IPAL or sponsor -approved equivalent. All study  interventions will be accounted for 
using a study intervention accountabilit y form /record.
7.Further guidance and information for the final disposition of unused study  
interventions are provided in the I P manual. All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
invest igator must ensure that the materials are destroy ed in compliance with 
applicable environmental regulations, institutional policy , and any  special 
instructions provided by  Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 busi ness day  of 
discovery  as described in the I P manual.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by qualified 
staff. Dispensing is defined as the provision of study intervention, concomitant treatments, 
and accompan ying information by  qualified staff member(s) to a healthcare provider, 
participant in accordance with this protocol. L ocal health authority  regulations or investigator 
site guidelines may  use alternative terms for these activities.
The tablets/capsules will be provided in unit dose containers and labeled in accordance with 
Pfizer regulations and the clinical site’s labeling requirements. 
Study intervention should be prepared and dispensed by  an appropriatel y qualified and 
experienced member of the study  staff (eg, physician, nurse, phy sician’s assistant, nurse 
practitioner, pharmacy  assistant/technician, or pharmacist) as allowed by  local, stat e, and 
institutional guidance. A second staff member will verify  the dispensing .
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Study Intervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participants are enrolled.
The investigator will assign participant numbers to the participants as they  are screened for 
the study . All participants enrolled will receive treatment according to t he dose/schedule.
6.4. Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic w ill be recorded in the source documents and recorded in the CRF. 
The dose of stud y intervention and study participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 47study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  intervention was ingested.
6.5.Dose Modification 
No dose modification is anticipated .
6.6.Continued Access to Study Intervention After the End of the Study
No interve ntion will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07321332 greater than 600 mg or ritonavir greater than 
200mg within a 24 -hour time period (2 hours) w ill be conside red an overdose.
An accidental overdose of dabigatran may  lead to hemorrhagic complications. I n the event of 
hemorrhagic complications, initiate appropriate clinical support, discontinue treatment, and 
investigate the source of bleeding. For dabigatran, a specific reversal agent (idarucizumab) is 
available.9
There is no specific treatment for an overdose of either PF -07321332 or ritonavir.  
In the event of an overdose, the investigator should:
1.Contact the Pfizer medical monitor within 24 hours.
2.Closely  mon itor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF -07321332 or ritonavir 
(whichever is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to Pfizer Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within 1 day s from the date of the last dose of 
study  intervention if requested by  the medical monitor (determined on a case-by-case 
basis)
.
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the medical monitor based on the clinical evaluation of the participant.
6.8.Concomitant Therapy
Use of prescription or nonpre scription drugs and dietary  and herbal supplements are 
prohibited within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention. L imited use of nonprescription medications that are not believed to affect 
participant safe ty or the overall results of the study may be permitted on a case -by-case basis 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 48following approval b y the sponsor .Acetaminophen/paracetamol may  be used at doses 
of≤1g/day .
Herbal supplements and hormonal methods of contraception (including oral and tran sdermal 
contraceptives, injectable progesterone, vaginal ring, and postcoital contraceptive methods)
and hormone replacement therap y must have been discontinued at least 28 days prior to the 
first dose of investigational product.
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of study  intervention will be 
documented as a prior treatment. Treatments taken after the first dose of study  intervention 
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-07321332 or ritonavir . For 
dabigatran, the specific reversal agent (idarucizumab) is available.9Standard medical 
supportive care must be provided to manage the AEs. 
7.DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Study Intervention
It may  be necessary  for a participant to permanently  discontinue study  intervention .Reasons 
for permanent discontinuation of study  inter vention include the following: 
AE requiring discontinuation in investigator’s view,
Pregnancy ,
Positive COVI D-19 test.
If a positive COVID -19 test is confirmed during study  conduct, and if in the opinion of the
Principal I nvestigator ,in consultation with the sponsor, it is in the best interest of either the 
participant or the investigational site to discontinue, then the participant should be 
discontinued from the study . 
If study  intervention is permanentl y discontinued, the participant will not remain i n the study  
for further evaluation. See the SoA for data to be collected at the time of discontinuation of 
study  intervention.
In the event of discontinuation of study  intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 49receipt of stud y intervention or also from study  procedures, posttreatment study  follow-up, 
and/or future collection of additional information.
If a participant uses prohibited medication, guidance in Appendix 8should be followed.  
7.1.1. ECG Changes
A participant who meet s either bulleted criterion based on the average of triplicate ECG 
readings will be withdrawn from the stud y intervention. 
QTcF >500 msec.
Change from baseline: QTcF >60 msec and QTcF >450 msec.
If a clinically  significant finding is identified (including, but not limited to, change s from 
baseline in QTcF after enrollment), the investigator or qualified designee will determine if 
the participant can continue in the study  and if any change in participant management is 
needed. This review of the ECG printed at the time of collection mu st be documented. Any  
new clinicall y relevant finding should be reported as an AE.
7.1.2. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other ca uses of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µmol/L ) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [or ≥26.5 µmol/L ] in SCr 
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µmol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as p ossible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, detailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should in clude serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be considered potential cases of drug- induced kidney  injury  irrespective of 
availability  of all the results of the in vestigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants are noted to have 2 consecutive SCr results of 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 50≥0.3 mg/dL (or ≥26.5 µmol/L), an assessment of whether the finding may be considered an 
adverse drug reaction should be undertaken.
7.1.3. Liver Injury
Reasons for permanent discontinuation of study  intervention due to potential liver injury  are 
described in Appendix 6.
7.2.Participant Discontinuation/Withdrawal From the Study 
A participant may withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further stud y procedures;
Lost to follow -up;
Death;
Study  terminated by  sponsor;
Investigator decision .
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow
-up and for an y further evaluations that need to be completed. 
The early discontinuation visit applies only  to participants who are enrolled/randomized and 
then are prematurely  withdrawn from the study . Participants should be questioned regarding 
their reason for withdrawal. 
If aparticipant withdraws from the study , he/she may  request destruction of any  remaining 
samples taken and not tested, and the investigator must document any  such requests in the 
site study  records and notify  the sponsor accordingly .
If the participant withd raws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Consent 
Participants who request to discontinue receipt of study  intervention will remain in the stu dy 
and must continue to be followed for protocol specified follow -up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by  the participant to provide this 
information. Participants should notify  the investigator in writing of the decision to withdraw 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 51consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Follow -Up 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and resche dule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or should 
continue in the study .
Before a participant is deemed lost to follow-up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These c ontact attempts should be documented 
in the participant’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate d elegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y specific procedures. 
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud y design requirements, including those sp ecified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screenin g log to 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 52record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they  meet the study  population criteria for the study . If the time between 
screening and dosing exceeds 28 days as a result of unexpected delay s (eg, delay ed drug 
shipment), then participants do not require rescreening if the laboratory  results obtained prior 
to first dose administration meet eligibility  criteria.
Every  effort should be made to ensure that protocol required- tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the contr ol of the investigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol required test cannot be performed, the 
investigat or will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.
If an IV catheter is utilized for blood sample collections, ECGs and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.
For samples being collected and shipped, detailed collection, processing, storage, a nd 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participants in this study  is approximately  
470mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y Pfizer, provided the total 
volume taken during the study  does not exceed 550 mL during an y period of 60 consecutive 
days.
To prepare for stud y participation, participants will be instructed on the information in 
Protocol Section 5.3 Lifesty le Considerations and Section 6.8 Concomitant Therap y.
8.1.Efficacy Assessments
Not applicable.
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 538.2.1. Physical Examinations
A complete PE will include, at a minimum, head, ears, ey es, nose, mouth, skin, heart and 
lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and neurological 
systems. A medical history  will als o be collected including smoking status and alcohol use.
A brief PE will include, at a minimum, assessments of general appearance, the respiratory  
and cardiovascular s ystems, and participant reported sy mptoms. 
PEs may  be conducted by  a phy sician, trained phy sician ’ s assistant, or nurse practitioner as 
acceptable according to local regulation. 
Height and weight will also be measured and recorded as per the SoA. For measuring weight, 
a scale with appropriate range a nd resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulk y layers of clothing, and jackets so that only  
light clothing remains. They  must also remove the contents of their pockets and remain still 
during measurement of weight. 
PE findings collected during the stud y will be considered source data and will not be required 
to be reported, unless otherwise noted. An y untoward PE findings that are identified during 
the active collection period and meet the definiti on of an AE or SAE ( Appendix 3 ) must be 
reported according to the processes in Section 8.3.1 to Section 8.3.3.
8.2.2. Vital Signs
Supine BP will
be measured with the participant’s arm supported at the level of the heart and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 
(preferabl y the dominant arm) will be used throughout the study . Participants should be 
instru cted not to speak during measurements. 
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection. 
Additional collection times, or changes to collection times, of BP and pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
8.2.2.1. Respiratory Rate 
Respiratory  rate will be measured after approximately  5minutes of rest in a supine position 
by observing and counting the respirations of the participant for 30 seconds and multiply ing 
by2. When BP is to be taken at the same time, respiration measurement will be done during 
the 5 minutes of rest and before BP measurement.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 548.2.2.2. Temperature
Temperature will be meas ured orall y (other bod y locations, eg ,tympanic, are acceptable 
provided the same method is used and documented throughout the stud y). No eating, 
drinking, or smoking is allowed for 15 minutes prior to the measurement.
8.2.3. Electrocardiograms
Standard 12- lead E CGs utilizing limb leads (with a 10 second rh ythm strip) should be 
collected at times specified in the SoA section of this protocol using an ECG machine that 
automatically  calculates the heart rate and measures PR, QT, and QTc intervals and QRS 
complex. Alternative lead placement methodology  using torso leads (eg, Mason- Likar) 
should not be used given the potential risk of discrepancies with ECGs acquired using 
standard limb lead placement. All scheduled ECGs should be performed after the participant 
has rested quietl y for approximately  10minutes in a supine position. 
Triplicate 12 -lead ECGs will be obtained approximately  2to 4minutes apart; the average of 
the triplicate ECG measurements collected before dose administration on Day 1of each 
period will serve as each participant ’s baseline QTc value.
To ensure safet y of the participants, a qualified individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will oc cur if a) a 
post-dose QTcF interval is increased b y ≥60msec from the baseline andis >450 msec for 
participants with normal renal function and >470 msec for participants with impaired renal 
function; or b) an absolute QT value is ≥500 msec for an y schedul ed ECG. If either of these 
conditions occurs, then 2 additional ECGs will be collected approximately  2to 4minutes 
apart to confirm the original measurement. If the QTc values from these repeated ECGs 
remain above the threshold value, then a single ECG mu st be repeated at least hourl y until 
QTc values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a) a postdose QTcF interval remains ≥60msec from the baseline andis >450 msec for 
participants with normal ren al function and >470 msec for participants with impaired renal 
function; or b) an absolute QT value is ≥500 msec for an y scheduled ECG for greater than 
4 hours (or sooner, at the discretion of the investigator); or c) QTcF intervals get 
progressivel y longe r, the participant should undergo continuous ECG monitoring. A 
cardiologist should be consulted if QTcF intervals do not return to less than the criteria listed 
above after 8 hours of monitoring (or sooner, at the discretion of the investigator). 
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads be placed in the 
same positions each time in order to achieve precise ECG recordings. If a machine r ead-QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern are listed in Appendix 7.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 558.2.4. Clinical Safety Laboratory Assessments
SeeAppendix 2for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency. All protocol required laboratory  assessments, as defined in 
Appendix 2, must be conducted in accordance with the laboratory  manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study  
to assess an y perceived safet y issues. 
The investigator must review the laboratory  report, document this review , and record an y 
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  the investigator to b e more severe than expected for 
the participant ’s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 48 hours after the last dose of study intervention should 
be repeated unt il the values return to normal or baseline or are no longer considered clinicall y 
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiolog y should be identified and the sponsor notified.
For an y of the clinical safety laboratory assessments, if a result is outside the normal limit, 
the principal investigator in consult with the Pfizer medical monitor can make a decision 
regarding clinical significance. 
See Appendix 6for suggested actions and follow -up assessments in the event of potential 
drug-induced liver injury.
Urine drug (mandatory ) and alcohol breath test (at discretion of investigator) will be
performed at Screening and on Day  -1. These tests may  be performed at any  other time at the 
discretion of the investigator.
8.2.5. COVID -
19 Specific Assessments 
Participants will be tested for SARS -COV -2 infection by  RT-PCR prior to being admitted to 
the clinic for confinement and a subsequent SARS -CoV -2 test or rapid testing assessment 
(eg, Abbot) will be performed after 4 day s (ie, upon completion of 4 × 24 hours in house), or 
if they  develop COVID- 19 like sy mptoms. Additi onal testing may  be required by  local 
regulations or b y the Principal Investigator.
8.2.6. Pregnancy Testing 
Pregnancy  tests may  be urine or serum tests, but must have a sensitivity  of at least 
25mIU/mL. Pregnancy  tests will be performed in WOCBP at the times l isted in the SoA . 
Following a negative pregnancy  test result at screening, appropriate contraception must be 
commenced and a second negative pregnancy test result will be required at the baseline visit 
prior the participant’s receiving the study intervention. Pregnancy  tests will also be done 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 56whenever 1 menstrual cycle is missed during the active treatment period (or when potential 
pregnancy  is otherwise suspected) and at the end of the study . Pregnancy  tests may also be 
repeated if requested b y IRBs/E Cs or if required by local regulations. If a urine test cannot be 
confirmed as negative (eg, an ambiguous result), a serum pregnancy  test is required. In such 
cases, the participant must be excluded if the serum preg nancy  result is positive.
The pregnancy  test outcome should be documented in the participant’s source 
documents/medical records and relevant data recorded on the CRF. The investigator, or his 
or her designee, will confirm that the participant is adhering t o the contraception method(s) 
required in the protocol. The required frequency  of pregnancy  testing for this study  is 
described in the SoA.
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting
The def initions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  the 
participant (or, when appropriate, b y a caregiver, surrogate, or the partic ipant ’s legally  
authorized representative), or they  may  arise from clinical findings of the investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to ass ess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study  intervention (see Section 7.1). 
During the active collection period as described in Section 8.3.1, each participant will be 
questioned about the occurrence of AEs i n a nonleading manner.
In addition, the investigator may  be requested by  Pfizer Safet y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant’s participation in the study  (ie, before undergoing 
any study  related pro cedure and/or receiving study  intervention), through and including a 
minimum of 28 calendar days, except as indicated below, after the last administration of the 
study  intervention.
Follow -up by  the investigator continues throughout and after the active co llection period and 
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the 
investigator.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 57For participants who are screen failures, the active collection period ends when screen failure 
status is determined.
If the participant withdraws from the study  and also withdraws consent for the collection of 
future information, the active collection period ends when consent is withdrawn.
If a participant permanently  discontinues or temporaril y discontinues study intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.
Investigators are not obligated to activel y seek information on AEs or SAEs after the 
participant has concluded study participation . However, if the investigator learns of any  SAE, 
including a death, at an y time after a participant has completed the stud y, and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to Pfizer using the CT SAE Report Form.
8.3.1.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.1 are reported to Pfizer Safety  on the CT SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any  updated SAE data to the sponsor within 
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.1 ,will be recorded 
on the AE section of the CRF.
The investigator is to record on the CRF all directly  observed, and all spontaneously  reported 
AEs and SAEs reported by  the participant.
Reporting of AEs and SAEs for participants who fail screening are subject to the CRF 
requirements as describ ed in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 588.3.3. Follow -up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilizatio n, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality . Any information relevant to the event, such as concomitant medications 
and illnesses, must be pro vided. In the case of a participant death, a summary  of available 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3.
8.3.4. Regulato
ry Reporting Requirements for SAEs
Prompt notification by  the investigator to the sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities toward the safet y of participants and the safet y of 
astudy  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, IRBs/ECs , and investigators.
Investigator safety  reports must be prepared for SUSARs according to local regulatory  
requirements and sponsor policy  and forwarded to i nvestigators as necessary.
An investigator who receives SUSARs or other specific safet y information (eg, summary or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study  and will notify  the IRB/EC, if appropria te according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact with or exposure to the study  intervention. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. 
Anenvironmental exposure ma y include exposure during pregnancy, exposure during 
breastfeeding, and occupational exposure.
Any such exposure to the study  intervention under study  are reportable to Pfizer Safet y 
within 24 hours of investigator awareness.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 598.3.5.1. Exposure During Pregnancy
An EDP occurs if: 
A female participant is found to be p regnant while receiving or after discontinuing 
study  intervention.
A male participant who is receiving or has discontinued study  intervention exposes 
afemale partner prior to or around the time of conce ption. 
A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP: 
A female family  member or healthcare provider reports that she is pregnant af ter 
having been exposed to the study  intervention by  ingestion, inhalation or skin 
contact .
A male famil y member or healthcare provider who has been exposed to the study 
intervention by  ingestion , inhalation or skin contact then exposes his female 
partner prior to or around the time of conception. 
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information rel ated to 
termination of pregnancy). 
If EDP occurs in a participant or a participant’s partner, the investigator must report 
this information to Pfizer Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected after the start of study  intervention and until 28 day s after 
the last dose. 
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to Pfizer Safety  using the CT SAE Rep ort Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator si te file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as 
afollow -up to the initial EDP Supplemental Form. I n the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specifie d and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 60preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outc omes are considered SAEs. If the outcome of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a liveborn bab y, a terminated fetus, 
anintrauterine fetal demise, or a neonatal death), the investigator should follow the 
procedures for reporting SAEs. Additional information about pregnancy  outcomes that are 
reported to Pfizer Safet y as SAEs follows: 
Spontaneous abortion including miscarriage and missed abortion.
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibl y related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  the sponsor. Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmen tal delay s). In the case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was gi ven the Pregnant Partner Release of Information Form to provide to his 
partner.
8.3.5.2. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female participant is found to be breastfeeding while receiving or after 
discontinuing study  interv ention.
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by ingestion, inhalation, or skin contact. 
The investigator must report exposure during breastfeeding to Pfizer Safety  within 24 hours 
of the investigator’s awareness, irres pective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occurs in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the study ,so the information is not recorded on 
aCRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigator site file.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 61An exposure during breastfeeding report is not created when a Pfizer drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure
The investigator must report any  instance of occupational exposure to Pfizer Safet y within 
24hours of the investigator’s awareness using the CT SAE Report Form regardless of 
whether there is an associated SAE. Since the information about the occupational expo sure 
does not pertain to a participant enrolled in the study , the information is not recorded on 
aCRF; however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file.
8.3.6. Cardiovascular and Death Events
Not applicable.
8.3.7. Disease Related -Events and/or Disease Related- Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
AESI s are examined as part of routine safet y data review procedures throughout the clinical 
trial and as part of signal d etection processes.
All AESI s must be reported as an AE or SAE following the procedures described in 
Section 8.3.1 through 8.3.4 . An AESI  is to be recorded as an AE or SAE on the CRF. In 
addition, an AESI  that is also an SAE must be reported using the CT SAE Report Form.
8.3.8.1. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population.
8.3.9. Medical Device Deficiencies
Not applicable.
8.3.10. Medication Errors
Medication errors may  result from the administration or consumption of the study  
intervention by  the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under study  may  occur in clinical trial settings, such as 
medication errors.

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 62Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to Pfizer Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
•Medication errors involving participant exposure to the study intervention.
•Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant.
For further clarification, a medication error is:
•Any preventable event causing or leading to inappropriate medication use or 
participant harm;
•When a participant misunderstood, could not read, was not aware of, or not given 
dosing instructions
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication error is recorded on the medication error page of the CRF and, if applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the CRF. 
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.
8.4. Pharmacokinetics 
8.4.1. Plasma for Analysis of PF-07321332, Ritonavir, and DabigatranBlood samples of approximately 4 mL, to provide a minimum of 1.5 mL of plasma will be 
collected for measurement concentrations of dabigatran (total), PF-07321332 and ritonavir as 
specified in the SoA. 
 
Instructions for the collection 
CCI
PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 63and handling of biological samples will be provided in the laboratory manual or by the 
sponsor. The actual date and time (24-hour clock time) of each sample will be recorded.
The actual times may change, but the number of samples will remain the same. All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing. Collection of samples up to and including 10 hours after dose administration that are obtained within 10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 minute sample) will not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. Collection of samples more than 10 hours after doseadministration that are obtained ≤1 hour away from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on the source document and the CRF. 
 
 
 
 
Genetic analyses will not be performed on these plasma samples unless consent for this was 
included in the informed consent. Participant confidentiality will be maintained.
 
 
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity. Any deviations from the PK sample handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor. On a case-by-case basis, the sponsor may make a determination as to whether sample integrity has been compromised.
 
 
 CCI
CCI
CCI
PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 64 
 
 
 
 
8.7. Immunogenicity Assessments
Immunogenicity assessments are not included in this study.
8.8. Health Economics
Health economics/medical resource utilization and health economics parameters are not 
evaluated in this study.
9. STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of the data collected in this study 
is outlined here and further detailed in the SAP, which will be maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.
9.1. Statistical Hypotheses
No statistical hypothesis will be  tested in this study.
9.2. Analysis Sets
For purposes of analysis, the following analysis sets are defined:
Participant Analysis Set Description
PK Concentration The PK concentration population is defined as all 
participants assigned to investigational product and treated who have at least 1 concentration measured.CCI
CCI
CCI
CCI
CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 65Participant Analysis Set Description
PK Parameter The PK parameter anal ysis population is defined as all 
participants assigned to investigational product and 
treated who have at least 1 of the PK parameters of 
primary  interest measured.
Safety  Anal ysis Set All participants randomly  assigned to study  intervention 
and who take at least 1 dose of study  intervention. 
Participants will be anal yzed according to the product 
they actuall y received.
9.3. Statistical Analyses
The SAP will be developed and finalized before any  anal yses are performed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. Pharmacok inetic Analyses
9.3.1.1. Derivation of Pharmacokinetic Parameters Prior to Analysis
The plasma PK parameters for PF-07321332, ritonavir, and dabigatran (total) will be derived 
from the concentration time profiles as detailed in Table 1for each anal yte and treatment . 
Actual PK sampling times will be used in the derivation of PK parameters. I n the case that 
actual PK sampling times are not available, nominal PK sampling time will b e used in the 
derivation of PK parameters.
Table 1. Plasma PK Parameters
Param eter Analyte Definition Method of Determ ination
AUC last dabigatran Area under the plasma 
concentration -time profile 
from time 0to the time of 
the last quantifiable 
concentration (C last)Linear/Log trapezoidal method.
AUC inf dabigatran Area under the plasma 
concentration -time profile 
from time 0 extrapolated to 
infinite timeAUC last+ (C last*/k el), Where C last* is 
the predicted plasma concentration 
at the last quantifiable time point 
estimated from the log -linear 
regression analysis .
AUC tau PF-07321332 and 
ritonavirArea under the plasma 
concentration -time profile 
from time 0to time tau ( τ) 
the dosing interval, where 
tau=12 hou rs for BID 
dosing.Linear/Log trapezoidal method.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 66Table 1. Plasma PK Parameters
Param eter Analyte Definition Method of Determ ination
Cmax PF-07321332, ritonavir, 
dabigatranMaximum plasma 
concentrationObserved directly from data.
Tmax PF-07321332, ritonavir, 
dabigatranTime for C max Observed directly from data as time 
of first occurrence.
t½aPF-07321332, ritonavir, 
dabigatranTerm inal elimination 
half-lifeLog e(2)/k el, where k elis the terminal 
phase rate constant calculated by a 
linear regression of the log -linear 
concentration -time curve. Only 
those data points judged to des cribe 
the terminal log -linear decline w ill 
be used in the regression.
CL/FaPF-07321332, ritonavir, 
dabigatranApparent clearance Dabigatran (SD): Dose/AUC inf
PF-07321332 and ritonavir (MD): 
Dose/AUC tau
Vz/FaPF-07321332, ritonavir, 
dabigatranApparent volume of 
distributionDabigatran (SD): Dose/(AUC inf•kel)
PF-07321332 and ritonavir (MD): 
Dose/(AUC tau•kel)
a.If data permit.
9.3.2. Statistical Methods for PK Data
The plasma concentrations of PF-07321332, ritonavir and dabigatran will be listed and 
descriptivel y summarized by nominal PK sampling time and treatment. Individual 
participant, as well as mean and median profiles of the plasma concentration time data will 
be plotted by  treatment for each anal yte using actual (for indivi dual) and nominal (for mean 
and median) times respectively . Mean and median profiles will be presented on both linear 
and semi -log scales. For comparison of AUC infand C max with and without dabigatran, box 
and whisker plots of these parameters will be plot ted by  treatment for each anal yte. 
Natural log transformed parameters (AUC inf[if data permit) ]
,AUC last, and C max) of 
dabigatran will be anal yzed using a mixed effect model with treatment, period and sequence 
as fixed effects and participant within sequence as a random effect. Estimates of the adjusted 
mean differences (Test -Reference) and corresponding 90% CIs will be obtained from the 
model. The adjusted mean differences and 90% CIs for the differences will be exponentiated 
to provide estimates of the r atio of adjusted geometric means (Test/Reference) and 90% CI 
for the ratios. Dabigatran administered alone will be the reference treatment and 
PF-07321332/ritonavir co- administered with dabigatran and ritonavir co -administered with 
dabigatran will be the t est treatments.
Additional specifications about the tables, listings, and figures will be outlined in the SAP.

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 679.3.3. Other Safety Analyses
All safety analyses will be performed on the safety population.
AEs, ECGs, vital signs (BP, pulse rate, RR and temperature) and safety laboratory data will 
be reviewed and summarized on an ongoing basis during the study to evaluate the safety of participants. Any clinical laboratory, ECG, BP, and pulse rate abnormalities of potential clinical concern will be described. Safety data will be presented in tabular and/or graphical format and summarized descriptively, where appropriate.
Medical history and PE and neurological examination information, as applicable, collected 
during the course of the study will be considered source data and will not be required to be reported, unless otherwise noted. However, any untoward findings identified on physical and/or neurological examinations conducted during the active collection period will be captured as AEs, if those findings meet the definition of an AE. Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory data, ECGs, and vital signs, will be considered source data, and will not be required to be reported, unless otherwise noted. Demographic data collected at screening will be reported.
All safety analyses will be summarized in accordance with Pfizer implemented CDISC 
Standards. All participants who receive IP (safety population) will be included in the safety analyses. All safety data will be summarized descriptively through appropriate data tabulations, descriptive statistics, categorical summaries, and graphical presentations.
The incidence of the primary safety endpoints of TEAEs and SAEs, as well as SAEs and AEs 
leading to discontinuation will be summarized for each dose group.
 
 
9.4. Interim Analyses
No formal interim analysis will be conducted for this study. As this is an open-label study, 
the sponsor may conduct unblinded reviews of the data during the course of the study for the purpose of safety assessment, facilitating PK/PD modeling, and/or supporting clinical development.
9.5. Sample Size Determination
A sample size of approximately 24 participants will provide adequate precision to estimate 
the effects of multiple dose PF-07321332/ritonavir on the PK of single dose dabigatran. The expected widths of the 90% CIs with 80% coverage probability are shown in the following table for a range of possible effects. CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 68Parameter Estimated Effect 
(100*Test/Reference)90% CI CI Width
AUC inf 80%
100%
120%
140%
160%
180%63.09%, 101.45%
78.86%, 126.81%
94.63%, 152.17%
110.40%, 177.53%
126.17%, 202.89%
141.95%, 228.26%38.36%
47.95%
57.54 %
67.13 %
76.72 %
86.31%
Cmax 80%
100%
120%
140%
160%
180%60.49%, 105.80%
75.61%, 132.25%
90.74%, 158.70%
105.86%, 185.15%
120.98%, 211.60%
136.10%, 238.06%45.31%
56.64%
67.97 %
79.30 %
90.62 %
101.95%
These estimates are based on the assumption that within -participant standard deviations are 
0.452 and 0. 532for lnAUC infand lnC max, respectively , as obtained from the mean of 2 
clinical stud ies(B1871043 and B7451026) and literature4in healthy  participants.
Participants who withdraw from the stud y ma y be replaced at the discretion of the Principal 
investi gator upon consultation with the sponsor.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 6910. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with th e protocol and with the following:
Consensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and CI OMS International Ethical Guidelines;
Applicable ICH GCP guidelines;
Applicable laws and regulations, including applicable privacy  laws.
The protocol, protocol amendments, I CD, SRSD(s), and other relevant documents 
(eg,advertisements) must be reviewed and approved by  the sponsor, submitted to an I RB/EC 
by the investigator, and reviewed and approved by  theIRB/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary  to eliminate an immediate 
hazard to study  participants.
Protocols and any substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  participants.
The investigator will be responsible for the following:
Providing wr itten summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  the IRB/EC;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations.
10.1.1.1.
Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an appl icable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately . 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 70In addition, the i nvestigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious breaches of this protocol or of the ICH GCP guidelines that the investigat or 
becomes aware of.
10.1.2. Informed Consent Process
The investigator or his/her representative will explain the nature of the study, including the 
risks and benefits, to the participant and answer all questions regarding the study . The 
participant should be give n sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed that their participation is voluntary . Participants will be 
required to sign a statement of informed consent that mee ts the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant is fully  informed about the nature 
andobjectives of the study , the sharing of data related to the study , and possible risks 
associated with participation, including the risks associated with the processing of the 
participant’s personal data. 
The participant must be informed that his/her pers onal study  related- data will be used by  the 
sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assurance auditors or other authorized personnel appointed by  the sponsor, by  
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant is fully  informed about his or 
her right to access and correct his or her personal data and to withdraw consent for the 
processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in t he study  and the date on which the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their 
participation in the study .
A cop y of the ICD(s) must be provided to the participant.
Participants who are rescreened are required to sign a new ICD.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 7110.1.3. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in encry pted electronic form and/or 
paper and will be password- protected or secured in a locked room to ensure that only  
authorized st udy staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be resp onsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  law.
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant specific- numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the numerical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  this single, participant specific -code. The study  site will 
maintain a confidential list of participants who participated in the study , linking each 
participant’s numerical code to his or her actual identity  and medical recor d ID. In case of 
data transfer, the sponsor will protect the confidentiality of participants’ personal data 
consistent with the clinical study  agreement and applicable privacy  laws.
10.1.4. Committees Structure
10.1.4.1. Data Monitoring Committee 
This study  will not use a DMC.
10.1.5. Dissemination of Clinical Study Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, accu rate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer -sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These results are 
submitted for posting in accordance with the format and timelin es set forth by  US law.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 72EudraCT
Pfizer posts clinical trial results on EudraCT for Pfizer -sponsored interventional studies in 
accordance with the format and timelines set forth by  EU requirements.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for Pfizer 
sponsored interventional studies at the same time the corresponding study  results are posted 
to www.clinicaltrials.gov .
Docum ents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this policy , includes clinical 
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol 
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this 
policy , includes the publishing of individual participant data. Policy  0070 applies to new 
marketing authorization applications submitted via the centralized procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 01 July 2015.
Data sharing
Pfizer provides researchers secu re access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contributes to the scientific understanding of the 
disease, target, or compound class. Pfizer will make data from these trials available 
24months after study  completion. Participant level- data will be anon ymized in accordance 
with applicable privacy  laws and regulations. CSRs will have personall y identifiable 
information redacted.
Data requests are considered from qualified researchers with the appropriat e competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purp oses.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that dat a entries are accurate and correct by  physically  or 
electronically  signing the CRF.
Guidance on completion of CRFs will be provided in the CRF Completion Requirements 
document.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 73The investigator must ensure that the CRFs are securel y stored at the study site in encry pted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study . Important deviations 
from the QTLs and a ny remedial actions taken will be summarized in the clinical study  
report.
The investigator must permit study  related- monitoring, audits, I RB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verificatio n may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring deta ils describing strategy , including definition of study  critical data items and 
processes (eg, risk based -initiatives in operations and quality , such as risk management and 
mitigation strategies and anal ytical risk based- monitoring), methods, responsibili ties, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual, or on -site monitoring), are provided in the data management plan and IQMP 
maintained and utilized by  the sponsor or designee.
The sponsor or des ignee is responsible for the data management of this study , including 
quality  checking of the data.
Records and documents, including signed ICDs, pertaining to the conduct of this study  must 
be retained b y the investigator for 15 years after study  completi on unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored securel y for as long as they are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 
with the sponsor or it s agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified
between the stud y data and the participant ’s medical records. The investigator will promptly  
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to an y such findings.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 7410.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documen ts are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Definition of what constitutes source data and its origin can be found in the Source 
Document Locator, which is maintained by  thesponsor .
Description of the use of the computerized sy stem is documented in the Source Document 
Locator, which is maintained by  the sponsor .
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors wil l perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the stu dy is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.8. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  atany 
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y site - closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor if 
requested to do so b y the responsible IRB/EC or if such termination is required to protect the 
health of study  participants.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 75Reasons for the earl y closure of a study  site by  the sponsor may  include but are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor ’s procedures, or the ICH GCP 
guidelines;
Inadequate r ecruitment of participants by  the investigator;
Discontinuation of further study  intervention development.
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IRB/ECs, the regulatory  authorities, and an y CRO(s) used in the study of 
the reason for termination or suspension, as specified by  the applicable regulatory  
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate participant therap y and/or follow -up.
Study termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1 year after the end of the study  
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequ ent publications, 
such as secondary  manuscripts, and submits all manuscripts or abstracts to the sponsor 
30days before submission. This allows the sponsor to protect proprietary  information and to 
provide comments, and the investigator will, on request, r emove any  previously  undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer -intervention 
related information necessary  for the appropriate scientific presentation or understanding of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors.
The sponsor will comply  with the requireme nts for publication of the overall study  results 
covering all investigator sites. I n accordance with standard editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data . In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with I nternational Committee of Medical Journal Editors authorship 
requirements. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 76If publication is addressed in the clinical study agreement, the p ublication policy  set out in 
this section will not apply.
10.1.10. Sponsor’s Qualified Medical Personnel
The contact information for the sponsor ’s appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in the CTMS sy stem. 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an ECC at the time of informed 
consent. The ECC contains, at a minimum, (a) protocol and study  intervention identifiers, (b) 
participant’s stud y identification number, and (c) site emergency phone number active 
24hours/day , 7days per week , and (d) Pfizer Call Center number.
The ECC is intended to aug ment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  healthcare 
professionals not involved in the research study  only , as a means of reaching the investigator 
or site staff related to the care of a participant .The Pfizer Call Center number should only  be 
used when the investigator and site staff cannot be reached. The Pfizer Call Center number is 
not intended for use b y the participant directly; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 7710.2. Appendix 2: Clinical Laboratory Tests
The following safety laboratory tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory results may be reported on these samples as a result of the method of analysis or the type of analyzer used by the clinical laboratory, or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical laboratory measurements may be obtained at any time during the study to assess any perceived safety issues.
Table 2. Protocol-Required Safety Laboratory Assessments
Hematology Chemistry U rinalysis Other
Hemoglobin
HematocritRBC count
MCV
MCHMCHCPlatelet countWBC count
Total neutrophils (Abs)
Eosinophils (Abs)Monocytes (Abs)Basophils (Abs)Lymphocytes (Abs)BUN/urea and creatinine
Glucose (fasting)Calcium
Sodium
PotassiumChlorideTotal CO
2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphataseCreatine kinaseUric acidAlbuminTotal proteinLocal Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)KetonesNitritesLeukocyte esterase
Laboratory:
Microscopy and 
culturea •SARS-CoV-2 RT-PCR
•TSH
•Free T4
•Urine drug screeningb
•Pregnancy test ( β-hCG)c
•aPTT
•PT-INR
•Fibrinogen
At screening only
•FSHd
•HIV
•HBsAg
•HBcAb
•HCVAb 
•HBsAbe
a. Only if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase and culture only if 
bacteriuria.
b. At screening and Day -1; The minimum requirement for drug screening includes cocaine, THC, 
opiates/opioids, benzodiazepines, and amphetamines (others are site and study specific).
c. Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/EC. Serum or urine β-hCG for female participants of childbearing potential. 
d. For confirmation of postmenopausal status only.
e. HBsAb will be performed as reflex testing for any participant who is HBsAg and HBcAb positive.
The investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safety laboratory 
measurements at baseline and at all times after dose administration may be retained and stored for the duration of the study.
 
 Samples to be used for this 
purpose will be shipped to either a Pfizer-approved BBS facility or other designated laboratory and retained for up to 1 year following the completion of the study.CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 7810.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study  
participant, temporally associated with the use of study intervention, whether or 
not considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
temporally associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or 
urinaly sis) or other safety  assessments (eg, ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator. Any  
abnormal laboratory  test results t hat meet an y of the conditions below must be 
recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either 
an increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration, 
even though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug –drug interaction.
Signs, sy mptoms, or the clinica l sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self
–harming intent. Such overdoses should be reported regardless of 
sequelae.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 79Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms 
of the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscopy , appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day–fluctuations o f preexisting disease(s) or condition(s) 
present or detected at the start of the study  that do not worsen.
10.3.2. Definition of an SAE
An SAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening-
The term “life -threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event that h ypotheticall y might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been admitted (usually  
involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospitalization are AEs. 
If a complication prolongs hospitalization or fulfills any  other serious criteria, the 
event is serious. When in doubt as to whether “hospitalization” occurred or was 
necessary , the AE should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 80d.Results in persistent or significant disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance, such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), that may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a Pfizer product of an infectious agent, 
pathogenic or non -pathogenic, is considered serious. 
The event may  be suspected from clinical s ymptoms or laboratory  findings 
indicating an infection in a participant exposed to a Pfizer product. The terms 
“suspected transmission” and “transmission” are considered s ynon ymous. These 
cases are considered unexpected and handled as serious expedited cases b y 
pharmacovigilance personnel. Such cases are also considered for reporting as 
product defects, if appropriate.
g.Other situations:
Medical or scientific judgment should be exercised by  the investigator in 
deciding whether SAE reporting is appropriate in other situations, such as 
significant medical events that may  jeopardize the participant or may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definition. These events should usually  be considered serious.
Examples of such events include invasive or maligna nt cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -up of AEs and /or SAEs During the Active 
Collection Period
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to Pfizer Safet y throughout the active 
collection period. These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonse rious AEs; and (3) exposure to the study  intervention under stud y during 
pregnancy  or breastfeeding, and occupational exposure. 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 81It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as the AE page of the CRF. When the same data are collected, the forms must 
be completed in a consistent manner. AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety Within 24 Hours 
of Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note: Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB are 
reported (w hether or not 
there is an associated 
SAE).**
Environmental or 
occupational exposure 
to the product under 
study  to a non -
participant (not 
involving EDP or EDB).None. Exposure to a study 
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
* EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report 
Form. 
** EDB is reported to Pfizer Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
*** Environmental or Occupational exposure : AEs or SAEs associated with occupational 
exposure are reported to Pfizer Safety using the CT SAE Report Form.
When an AE or SAE occurs, it is the responsibility  of the investigator to review 
all documentation (eg, hospital progress notes, laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 82It is notacceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF p age.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis 
(not the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asy mptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive intervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shopping for groceries or clothes, using the telephone, ma naging money , etc.
Severe: Severe or medically  significant but not immediately  life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling, limiting 
self care ADL. Self care ADL refers to bathing, dressing and undressing, feed ing 
self, using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
Theinvestigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that the re are facts, 
evidence, and/or arguments to suggest a causal relationship, rather than a 
relationship cannot be ruled out.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 83Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to stud y intervention 
administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for 
marketed products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. Howev er, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the 
sponsor.
The investigator may  change his/her opinion of causality  in light of follow -
up-informatio n and send an SAE follow -up-report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caus ed the 
event, then the event will be handled as “related to study  intervention” for 
reporting purposes, as defined by  the sponsor. In addition, if the investigator 
determines that an SAE is associated with study  procedures, the investigator 
must record thi s causal relationship in the source documents and CRF, and report 
such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of 
supplemental measurements and/or evaluations, as medically  indicated or as 
requested b y the sponsor, to elucidate the nature and/or causalit y of the AE or 
SAE as fully  as possible. This may  include additional laborator y tests or 
investigations, histopathological examinations, or consultation with other 
healthcare providers.
If a participant dies during participation in the study or during a recognized 
follow -up- period, the investigator will provide Pfizer Safety  with a copy of an y 
postmortem findings, including histopathology .

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 84New or updated information will be recorded in the originally  submitted 
documents.
The investigator will submit any  updated SAE data to the sponsor within 
24 hours of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety  will be the 
electronic data collection tool.
If the electronic s ystem is unavailable, then the site will us e the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data 
become available.
After the stud y is completed at a given site, the electronic data collection tool 
will be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives 
updated data on a previously  reported SAE after the electronic data collection 
tool has been taken off -line, then the site can report this information on a paper 
SAE form (see next section) or to Pfizer Safet y by telephone.
SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working, notification b y telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier service.
Initial notifi cation via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated 
reporting time frames.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 8510.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 28 day safter the last dose of stud y intervention, which
corresponds to the time needed to eliminate reproductive safet y risk of the study  
intervention(s):
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse with a female of childbearing potential as 
their preferred and usual lifesty le (abstinent on a long term- and persi stent basis) and 
agree to remain abstinent. 
OR
Must agree to use contraception/barrier as detailed below:
Agree to use a male condom and should also be advised of the benefit for a 
female partner to use a highl y effective method of contraception as a cond om may  
break or leak when having sexual intercourse with a woman of childbearing 
potential who is not currently  pregnant.
In addition to male condom use, a highl y effective method of contraception may be 
considered in WOCBP partners of male participants (r efer to the list of highly  
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion 
Criteria
A female participant is eligible to participate if she is not pregnant or breastfeeding, and at 
least 1 of the following conditions applies:
Is not a WOCBP (see definitions below in Section 10.4.3).
OR
Is a WOCBP and using a contraceptive method that is highly effective (with a failure 
rate of <1% per year), preferably with low user dependency , as described below 
during the intervention period and for at least 28 day safter the last dose of study  
interve ntion, which corresponds to the time needed to eliminate any  reproductive 
safet y risk of the stud y intervention(s). The investigator should evaluate the 
effectiveness of the contraceptive method in relationship to the first dose of study  
intervention.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 86A WOCBP agrees not to donate eggs (ova, oocy tes) for the purpose of reproduction during 
this period. The investigator should evaluate the effectiveness of the contraceptive method in 
relationship to the first dose of study  intervention.
The investigator is r esponsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregnancy . 
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the first dose of study  intervention, additional evaluation should be
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenopausal female with 1 of the following: 
Documented h ysterectomy ;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertili ty due to an alternate medical cause other than 
the above, (eg, m ullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
2.Postmenopausal female.
A postmenopausal state is d efined as no menses for 12 months without an 
alternative medical cause. I n addition:
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and not using hormonal 
contraception or HRT. 
A fem ale on HRT and whose menopausal status is in doubt will be required to 
use one of the non -estrogen hormonal highl y effective contraception methods 

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 87if they  wish to continue their HRT during the study . Otherwise, they  must 
discontinue HRT to allow confirmati on of postmenopausal status before study  
enrollment. 
10.4.4. Contraception Methods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependency 
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device.
3.Intrauterine hormone -releasing s ystem.
4. Bilateral tubal occlusion (eg, bilateral tubal ligation).
5.Vasectomized partner.
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The spermatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent 
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation.
Oral;
Intravaginal;
Transdermal;
7.Progestogen -only hormone contraception associated with inhibition of ovulation.
Oral;
Injectable.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 888.Sexual abstinence.
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide;
A combination of male con dom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods).

PF-07321332
Protocol C4671012Final Protocol, 03 August 2021
PFIZER CONFIDENTIAL
Page 89 
 
 
 
 
 
 
 
 
 
 CCI
PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 9010.6. Appe ndix 6: Liver Safety: Suggested Actions and Follow -Up Assessments
Potential Cases of Drug Induced- Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those wh o show transient liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious li ver injury , commonl y referred to as DILI. 
Participants who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptors” or are “susceptible.”
In the majority  of DILI cases, elevations in AST and/ or ALT precede T bili elevations 
(>2×ULN) b y several day
s or weeks. The increase in T bili ty pically  occurs while AST/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and T bili values will be elevated within the 
same laboratory  sample). I n rare instanc es, b
y the time T bili elevations are detected, 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI. 
Therefore, abnormal elevations in either AST OR AL T in addition to T bili that meet the 
criteria outlined below are co nsidered potential DILI (assessed per Hy ’s law criteria) cases 
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DIL I case depends on the 
participant’s individual baseline values and underlying conditions. Participants who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etio logy of the abnormal laboratory  values:
Participants with AST/ALT and T bilibaseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a T bili value 
>2×
ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participants with baseline AST OR ALT ORT b ili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preex isting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 91Rises in AST/AL T and T bili separated by more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awarenes
s of the abnormal results. This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and T bili for suspected Hy ’s law 
cases, additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for furt
her contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by  itself or as a coformulated 
product in prescription or over- the-counter –medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or all ergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection, liver imaging (eg, biliary  tract), and collection of serum 
samples for acetaminophen /paracetamol drug and
/or protein adduct levels may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
Tbili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnorm alities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 9210.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as AEs
Marked sinus brady cardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec (absolute) or by≥60msec from 
baseline.
New onset -atrial flutter or fibrillation, with controlled ventricular response rate:
ie, rate <120 bpm.
New onset -typeI second -degree -(Wenckebach) AV block of >30 seconds’ 
duration.
Frequent PVCs, triplets, or short intervals (<30 seconds) of consecutive 
ventricular complexes.
ECG Findings That May Qualify as SAEs
QTcF prolongation >500 msec.
New ST- T changes suggestive of my ocardial ischemia.
New onset - left bundle branch block (QRS >120 msec).
New onset - right bundle branch block (QRS >120 msec).
Symptomatic brady cardia. 
Asystole:
In awake, s ymptom free -participants in sinus rhy thm, with documented 
periods of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an 
escape rh ythm that is below the AV node. 
In awake, s ymptom free -participants with atrial fibrillation and brad ycardia 
with 1 or more pa uses of at least 5 seconds or longer. 
Atrial flutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained supraventricular tach ycardia (rate >120 bpm) (“sustained” = short 
duration with relevant symptoms or lasting >1minute).

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 93Ventricular rh ythms >30 seconds’ duration, including idioventricular rhy thm 
(heart rate <40 bpm), accelerated idioventricular rhy thm (HR >40 bpm to 
<100 bpm), and monomorphic/poly morphic ventricular tach ycardia (HR 
>100 bpm (such as torsades de pointes)).
Type IIsecond -degree -(Mobitz II) AVblock.
Complete (third- degree -) heart block.
ECG Findings That Qualify as SAEs
Change in pattern suggestive of new m yocardial infarction. 
Sustained ventricular tachy arrhy thmias (>30 seconds’ duration).
Second- or third -degree -AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring 
cardioversion.
Ventricular fibrillation/flutter.
At the discretion of the investigator, any  arrhy thmia classified as an adverse 
experience.
The enumerated list of major events of potential clinical concern are recommended as “alerts” or 
notifications from the core ECG laboratory to the investigator and Pfizer study team, an d not to be 
considered as all -inclusive of what to be reported as AEs/SAEs.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 9410.8. Appendix 8: Prohibited and Precautionary Concomitant Medications That May 
Result in DDI 
The prohibited concomitant medications listed below should not be taken with PF -
07321332, 
ritonavir or dabigatran during dosing and up to 4 day s after the final dose of ritonavir. 
The Pfizer study team is to be notified of any  prohibited medications taken during the stud y. 
This list of drugs prohibited or precautionary  for potential DDI concerns with the I MP may  
be revised during the course of the stud y with written notification from sponsor, to include or 
exclude specific drugs or drug categories for var ious reasons (eg, emerging DDI results for 
the IMP, availability  of new information in literature on the DDI potential of other drugs). 
This is not an all -inclusive list. Site staff should consult with the sponsor or designee with 
any questions regarding potential DDI.
Prohibited Medications
Medications that are Strong Inducers of CYP3A4a
Drug Class Specific Medication Clinical Comments
Anticoagulant Dabigatran Potential to impact the PK of 
PF-07321332 and ritonavir Anti -epileptic Phenytoin, carbam azepine
Herbal Products St. John's wort
Medications Dependent on CYP3A4 for Clearance, with Drug Interactions with
PF-07321332/ritonavira
Alpha 1 -Adrenoreceptor 
AntagonistAlfuzosin Risk of hypotension, syncope
Antianginal Ranolazine Risk of cardiac arrhythmias 
Antiarrhythmics Amiodarone, Bepridil, Flecainide, 
Propafenone, Quinidine, 
Dronedarone, EncainideRisk of cardiac arrhythmias 
Antihistamines Astemizole, Terfenadine Risk of cardiac arrhythmias
Ergot Derivatives Dihydroer gotamine, Ergonovine, 
Ergotamine, MethylergonovineRisk of acute ergot toxicity 
(peripheral vasospasm and ischemia 
of the extremities)
HMG CoA Reductase 
Inhibitors Lovastatin, Simvastatin Risk of rhabdomyolysis; consider 
alternative agent : pravastatin
Neuroleptic Pimozide Risk of cardiac arrhythmias 
PDE -5 inhibitors Sildenafil (Revatio) -PAH Risk of visual disturbances, 
hypotension, prolonged erection, and 
syncope
Sedatives/hypnotics Oral Midazolam, Triazolam Risk of prolonged sedation or 
respiratory depression
a.If a drug is not listed, it should not automatically be assumed it is safe to co -administer.

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 95Precautionary Medications
Medications to be Used with Caution when Co -administered with PF-07321332/ritonavi ra
Drug Class Specific Drugs Clinical Comments 
Anticonvulsants Lamotrigine, 
Valproate
Phenytoin
CarbamazepineCoadm inistration may decrease 
lamotrigine, valproate, and phenytoin 
concentrations. 
Coadm inistration may increase 
carbamazepine concentrations .Careful 
monitoring of adverse effects .
Alternative agents: Gabapentin 
Topiramate
Anti coagulants Rivaroxaban Increased risk of bleeding , subject should 
not be enrolled if on blood thinners .
Antidepressant Trazadone, Desipramine, Fluoxetine 
Paroxetine, SertralineMay increase antidepressant 
concentration .
Anti -infective Erythromycin Coadm inistration may increase 
erythromycin concentration. 
Antifungals Itraconazole
VoriconazoleCoadm inistration may increase 
itraconazole concentration. Monitor for 
adverse effects.
Coadm inistration may decrease 
voriconazole concentration .
Calcium Channel 
Blockers Diltiazem, Verapamil, Felodipine, 
Nicardipine, Nisoldipine , AmlodipineCoadm inistration may increase 
concentrations. The impact on the PR 
interval of co -administration of ritonavir 
with other drugs that prolong the PR 
interval (i ncluding calcium channel 
blockers) has not been evaluated. If 
coadministration is indicated, consider a 
dose reduction (amlodipine
recommended dose reduction of 50%). 
Close monitoring is recommended .
Cardiac Glycosides Digoxin Coadm inistration increases d igoxin 
concentration .
Hepatitis C direct 
acting antiviralsBoceprevir, Glecaprevir/Pibrentasvir
Simeprevir, 
Sofosbuvir/Velpatasvir/Voxilaprevir
Ombitasvir/Paritaprevir/ Ritonavir , 
DasabuvirCoadm inistration is not recommended as 
it resulted in increased plasma 
concentrations of Hep C antiviral; 
Caution or not recommended .
HIV Protease 
Inhibitors
NNRTs, Fusion 
InhibitorsLopinavir, Amprenavir, Indinavir, 
Nelfinavir, Saquinavir
Abacavir, Didanosine ,ZidovudineCoadm inistration may increase HIV 
protease inhibitor concentrations; 
coadminist ration with caution .
HMG CoA reductase 
inhibitorsAtorvastatin, Rosuvastatin Use with caution; risk of myopathy 
including rhabdomyolysis .Use low est 
dose of statin.
Alternative agents: Pravastatin .

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 96Precautionary Medications
Hypoglycemics Glipizide, Tolbutamide
RepaglinidePotentially decrease glipizide and 
tolbutamide concentrations. 
Potentially increase repaglinide 
concentrations. 
Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus Coadm inistration may increase 
immunosuppres sant concentrations. 
Narcotic Analgesics Methadone, Fentanyl Moderate to w eak decreases in 
methadone AUC have been observed
Fentanyl concentration may increase .
a.If a drug is not listed, it should not automatically be assumed it is safe to co -administer.
Prohibited Medications
Medications that are Strong Inducers of P -gp
Drug Class Specific Medication Clinical Comments
Antibiotic Rifampin Reduction to exposure of dabigatran
Medications that are Strong inhibitors of P -gp  
Antiarrhythmics amiodarone Increase exposures of dabigatran
Alpha/Beta Blocker carvedilol Increase exposures of dabigatran
Antibiotic clarithromycin Increase exposures of dabigatran
Calcium Channel Blocker verapamil Increase exposures of dabigatran
Protease Inhibitor ritonavir Increase exposures of dabigatran
Antifungal itraconazole Increase exposures of dabigatran

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 9710.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used 
in the protocol.
Abbreviation Term
 ongoing/continuous event
%CI confidence interval (%)
3CL 3C-like
3CLpro3C-like protein
Ab antibody
Abs absolute
ADL activities of daily living
AE adverse event
AESI adverse event of special interest
ALT alanine aminotransferase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
AUC area under the concentration -time curve
AUC inf area under the plasma concentration -time curve from time 0 extrapolated to 
infinity
AUC last area un der the plasma concentration time curve from time 0 to the time of the 
last measurable concentration
AUC tau area under the plasma concentration -time profile from time zero to time tau (τ) 
the dosing interval, where tau=12 hours for BID dosing
AV atrioventricular
BBS Biospecimen Banking System
-hCG beta-human chorionic gonadotropin
BID twice a day
BMI body mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
Cav average concentration during a dosing interval
CBC complete blood count
CDISC clinical data interchange standard consortium
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
CKD -EPI Chronic Kidney Disease -Epidemiology Collaboration
CL/F apparent clearance of drug from eg, plasma
Clast last observed (quantifiable) plasma concentration
Cmax maximum observed plasma concentration
CO 2 carbon dioxide (bicarbonate)
COVID -19 coronavirus disease 2019
CRF case report form
CRO contract research organization
CRU clinical research unit

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 98Abbreviation Term
CSR Clinical Study Report
CT clinical trial
CTMS clinical trial management system
CYP cytochrome P450
CYP3A cytochrome P450 3A
CYP3A4 cytochrome P450 3A4
CYP3A5 cytochrome P450 3A5
DDI drug-drug interaction 
DILI drug-induced liver injury
DMC Data Monitoring Committee
EC ethics committee
ECC Emergency Contact Card
ECG electrocardiogram
eCRF electronic case report form
EDB exposure during breastfeeding
EDP exposure during pregnancy
eGFR estimated glomerular filtration rate
EMA European Medicines Agency
EOT end of treatment
EU European Union
EudraCT European Clinical Trials Database
FIH first-in-human
fm fraction metabolized
FSH follicle stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
GLP Good Laboratory Practice
HBcAb hepatitis B core antibody
HBsAb hepatitis B surface antibody
HBsAg hepatitis B surface antigen
HcoV human coronavirus 
HcoV -229E human coronavirus 229E
HcoV -HKU1 human coronavirus HKU1
HcoV -NL63 human coronavirus NL63
HcoV -OC43 human coronavirus OC43
HCT hematocrit
HCV hepatitis C virus
HCVAb hepatitis C antibody
Hep C hepatitis C
HgB hemoglobin
HIV human immunodeficiency virus
HMG CoA 3-hydroxy -3-methyl -glutaryl -CoA
HR heart rate
HRT hormone replacement therapy
IB Investigator’s Brochure
ICD informed consent document

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 99Abbreviation Term
ICH International Council for Harmonisation
ID identification
IMP investigational medicinal product
IND Investigational New Drug 
INR international normalized ratio
IP investigational product
IPAL Investigational Product Accountability Log
IQMP Independent Qualified Medical Practitioners
IRB Institutional Review Board
IV intravenous
ka absorption rate constant
kel terminal phase rate constant calculated by a linear regression of the log -linear 
concentration -time curve.
Ki inhibition constant
kp, uu unbound partition coefficient
LBBB left bundle branch block
LFT liver function test
lnAUCinf log-transformed AUCinf
lnCmax log-transformed C max
MAD multiple ascending dose
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MD multiple dose
MERS Middle East respiratory syndrome
msec millisecond
N/A not applicable
NHP non-human primate
NNRT non-nucleoside reverse transcriptase 
NOAEL no observed adverse effect level
PAH pulmonary arterial hypertension
PD pharmacodynamic(s)
PDE phosphodiesterase
PE physical examination
P-gp P-glycoprotein
pH potential of hydrogen
PI principle investigator
PK pharmacokinetic(s)
PR pulse rate
PT prothrombin time
PT-INR prothrombin time -international normalized ratio
PVC premature ventricular contraction/complex
q12h every 12 hours
QT time from the beginning of the QRS complex to the end of the T wave
QTc corrected QT interval
QTcF corrected QT (Fridericia method)

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 100Abbreviation Term
qual qualitative
QTL quality tolerance limits
RBC red blood cell
RR respiratory rate
RT-PCR reverse -transcriptase polymerase chain reaction
SAD single ascending dose
SAE serious adverse event
SAP Statistical Analysis Plan
SARS -CoV -1 severe acute respiratory syndrome coronavirus 2
SARS -CoV -2 severe acute respiratory syndrome coronavirus 2
SCr serum creatinine
SD single dose
SoA schedule of activities
SOP standard operating procedure
SRSD single -reference safety document
SUSAR suspected unexpected serious adverse reaction
T1 Treatment 1
t½ terminal half -life
T2 Treatment 2
T3 Treatment 3
T4 thyroxine
Tbili total bilirubin
TEAE treatment emergent adverse event
THC tetrahydrocannabinol
Tmax time to first occurrence of C max
TSH thyroid stimulating hormone
UGT uridine 5’ -diphospho -glucuronosyltransferase
ULN upper limit of normal
US United States
USPI United States Prescribing Information
Vz/F apparent volume of distribution
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential

PF-07321332
Protocol C4671012
Final Protocol , 03August2021
PFIZER CONFIDENTIAL
Page 10111.REFERENCES
1Hsu A, Granneman G, Bertz R. Ritonavir: Clinical pharmacokinetics and interactions 
with other anti -HIV agents. Clin Pharmacokinet. 1998;35(4):275 -91.
2Kumar P, Gordon LA, Brooks KM, et al. Differential influence of the antiretroviral 
pharmacokinetic enhancers ritonavir and cobicistat on intestinal P -glycoprotein transport 
and the pharmacokinetic/pharmacod ynamic disposition of dabigatran. Antimicrob 
Agents Chemother. 2017;61(11):e01201-17. 
3Härtter S, Koenen -Bergmann M, Sharma A, et al. Decrease in the oral bioavailability  of 
dabigatran etexilate after co- medication with rifampicin. Br J Clin Pharmacol. 
2012;74(3): 490-500.
4Hartter S, Sennewald R, Nehmiz G et al. Oral bioavailability  of dabigatran etexilate 
(Pradaxa) after co ‑medication with verapamil in healthy  subjects. Br J Clin Pharmacol .
2013; 7
5(4):1053-62.
5World Health Organization. WHO Situation Report 51. 11 March 2020. Geneva, 
Switzerland: World Health Organization; 2020. Available from: 
https://www.who.int/emergencies/diseases/novel- coronavirus- 2019/situation -reports. 
Accessed: 29 March 2 020.
6Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) 
structure: basis for design of anti -SARS drugs. Science. 2003;300(5626):1763 -7.
7Kaletra (lopinavir/ritonavir) capsules . USPI. North Chicago, IL: AbbVie Inc.; 2013 
Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021226s038lbl.pdf.
8Pradaxa® (dabigatran etexilate) capsules. USPI . Ridgefield CT: Boehringer I ngelheim 
Pharmaceuticals, Inc.; 2021 Available from: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022512s041lbl.pdf.
9Praxbind® (I darucizumab) injection. USPI . Ridgefield CT: Boehringer Ingelheim 
Pharmaceuticals, Inc.; 2015 Available from:
https://www.accessdata.fda.gov/drugsatfda_docs/label/20 15/761025lbl.pdf. 
